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THE PARASYMPATHETIC NERVOUS SYSTEM  
IN HUMAN HEART FAILURE 
 
JESSICA A. FRENCH 
 
 
ABSTRACT 
 
Heart failure (HF) affects 5.8 million Americans and is characterized by an inability 
of the heart to pump blood throughout the body.  In a non-diseased state, the sympathetic 
(SNS) and parasympathetic nervous systems (PNS) innervate the heart to regulate rate 
and force of contraction.  Actions of the PNS on the cardiovascular system are mediated 
via the vagus nerve, releasing acetylcholine which binds muscarinic receptors on 
cardiomyocytes.  The SNS has been found to be overstimulated in HF, with the role of 
the PNS in HF unclear.  We hypothesized that the PNS is dysregulated in HF, resulting in 
a change of muscarinic receptor densities.  We measured total muscarinic receptor 
density on non-failing and failing human heart samples, and determined if demonstrated 
differences were reversed through mechanical unloading with a left ventricular assist 
device (LVAD).  Through radioligand binding assays, we found a significant increase in 
receptor density in failing human heart samples compared to control (275.8 ± 11.9 versus 
194.1 ± 17.3 fmol/mg protein; p<0.01), along with an increase in receptor density in 
 vii
failing with LVAD support samples(315.8 ± 23.9 versus 194.1 ± 17.3 fmol/mg protein; 
p<0.001). 
We also measured M1-M4 receptor subtypes on a subset of these samples.  While the 
percent of M1, M2, and M4 receptor subtypes did not significantly change between non-
failing, failing, and failing with LVAD support samples, the percent of M3 was 
significantly decreased in failure (8.61 ± 1.65 versus 13.56 ± 2.16 %; p<0.05) and 
increased back to non-failing percents in the failing + LVAD group (16.65 ± 0.72 versus 
8.61 ± 1.65 % in failure; p<0.01). 
Muscle function analysis was also performed.  Acetylcholine and isoproterenol were 
used to determine if a change in total muscarinic receptor density in groups related to a 
change in functional response on fresh trabecular muscles; with and without SNS 
stimulation.  Recovery in contractile parameters without SNS stimulation on ACh-treated 
muscles, and greater negative inotropic and chronotropic effects on ACh-treated muscles 
with SNS stimulation provide evidence that total muscarinic receptor density changes 
elicit different responses on the failing human heart. 
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CHAPTER I 
INTRODUCTION 
 
 
Heart failure (HF) is a condition affecting approximately 5.8 million Americans every 
year34.  670,000 new cases are diagnosed annually, and although there are treatment 
options, 1 in 5 people die within 1 year of diagnosis34.  Currently, implantable medical 
devices and drug therapy are used in the management of HF, however the prevalence of 
this syndrome continues to be overwhelmingly high.  In the heart, rate and force of 
contraction are regulated by the autonomic nervous system (ANS).  Areas of the ANS 
including the sympathetic nervous system (SNS) are altered in failure, which has led to 
new drug therapy targets.  The counterpart of the SNS, the parasympathetic nervous 
system (PNS), is not as well understood in HF.  With HF being one of the leading causes 
of mortality, it is important to expand research for more successful treatment options. 
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1.1  Human Heart Failure 
Heart failure (HF) is a disorder characterized by an inability of the heart to pump 
blood throughout the body40.  The onset of HF is gradual, and it is the most common 
diagnosis in patients over the age of 6540,18.  This syndrome is heterogeneous, with 
common symptoms such as breathlessness, fatigue, and fluid retention40.  
Cardiomyopathy is one diagnosis that leads to HF59.  There are different types of 
cardiomyopathy, such as ischemic and dilated cardiomyopathy.  As shown in Figure 1, 
these arise when the heart is enlarged and ventricular walls become thin and weakened.  
Ischemic cardiomyopathy occurs when the heart weakens due to coronary artery 
disease36.  Arteries block with plaque, causing the heart to have difficulty filling and 
pumping blood to the body36.  In dilated cardiomyopathy, the cause is often unknown36.  
Dilated cardiomyopathy can affect any age group, and can be genetic or caused by 
alcohol and drug abuse, stress, or a virus36. 
Molecularly, HF arises when myocytes undergo remodeling, meaning they change in 
size, shape, and function7.  Remodeling is an effect of cardiomyocytes responding to 
biomechanical stressors stimulating molecular and cellular events that lead to the 
characteristic failing heart7,43.  At first, these events are stimulated to compensate for the 
failing heart.  But after continual stimulation, they progressively exacerbate the disease 
and worsen prognosis.  These events are a complex series of interactions that mediate 
various responses on the heart, including rate and force of contraction.  Examples of 
important changes seen in HF include alterations in calcium-cycling proteins and 
autonomic nervous system regulation10,13,40. 
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     Failing Heart Non-Failing Heart 
 
 
 
 
 
 
 
 
Figure 1.  Non-Failing versus Failing Human Heart.  
Non-failing (NF) human hearts, about the size of a 
clenched fist, are significantly smaller than severely failing 
hearts.  Notable features of the failing heart include 
enlarged chambers and thinned ventricular walls.  (Figure 
modified from www.intensivecare.hsnet.nsw.gov.au) 
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Alterations in Ca++ signaling contribute to depressed contractility seen in HF.  Because 
of the complexity of Ca++ regulation in healthy hearts, it is difficult to pinpoint exact 
causes of reduced Ca++ transport in failure.  One mechanism involves the sarcoplasmic 
(endoplasmic) reticulum Ca++ ATPase protein SERCA.  Studies have shown a reduction 
in SERCA signaling in HF and improved contractility upon increased expression23,24.  
The protein that interacts with SERCA to inhibit reuptake of Ca++, phospholamban 
(PLB), is also a target of investigation.  Research supports that decreased levels of PLB 
play a role in decreased Ca++.  Along with finding decreased levels of SERCA and PLB, 
investigators have shown decreased expression of L-type Ca++ channels and ryanodine 
receptors (RYRs), and increased expression of Na+-Ca++ exchanger (NCX)23. 
The complexity of HF makes the condition difficult to treat.  Heart transplantation is 
the most effective form of treatment, yet only about 2,300 patients each year are able to 
receive a transplant21.  Drug therapy, surgery, and device therapy are currently the 
mainstay in managing HF. 
  
1.2  Left Ventricular Assist Devices (LVADs) 
Left ventricular assist devices, or LVADs, are surgically-implanted pumps that run via 
battery.  They take over pumping ability in severely failing hearts when heart 
transplantation is not presently available31.  During LVAD support, hearts are 
hemodynamically unloaded so they can continue to beat without having to perform work.  
As shown in Figure 2, LVADs are implanted from the apex of the left ventricle to the  
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Figure 2.  Left Ventricular Assist Device.  Although differing 
models of LVADs are available, typical devices are implanted 
from the apex of the left ventricle to the ascending aorta, with a 
pump lying in the abdomen or thoracic cavity.  These devices 
take the workload off of the left ventricles by allowing blood to 
flow through the left ventricle, while the device pumps the 
blood out to the aorta.  (Figure from www.heartfailure.org) 
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ascending aorta.  Blood is pumped from the lungs to the left atrium and into the left 
ventricle.  Blood is pulled from the left ventricle and into the device.  The device pumps 
blood into the aorta to be sent systemically through the body.  The pump’s battery and 
control system are kept outside the body, and are connected through a drive line to the 
pump inside the body. 
LVADs were first used as a bridge-to-transplant therapy for patients on the cardiac 
transplantation list.  However, research in the past decade has shown LVADs to increase 
survival rates and prognosis, leading to implantation of these devices as destination 
therapy20,48.   
 Rose et al found that patients with LVAD support survived a median 408 days while 
patients without a device survived a median 108 days48.  Physical ability exams and 
quality of life questionnaires were also examined from the same patient population, 
resulting in significantly higher physical function and qualities of life in patients with 
LVAD support. 
At the myocyte level, there is evidence that LVADs reverse remodeling of the failing 
heart.  In failing hearts treated with LVADs, contractile function of myocytes 
recovered20.  Contractile functions restored included the magnitude of shortening, and 
developed tension and relaxation rates20,42.  LVAD support also was found to improve 
neurohormonal systems, calcium handling, cytoskeletal protein abundance, and metabolic 
signaling12,14,20,28,53.  Beta-adrenergic receptor signaling, a component of the ANS, was 
also restored upon LVAD support42. 
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1.3  Autonomic Nervous System 
The ANS regulates functions of the body, including airflow, body temperature, 
digestion, blood pressure, and heart rate49.  It is often referred to as a ‘self-governing’ 
system and controls processes that are responsible for maintaining homeostasis49.  There 
are two major divisions of the ANS:  the sympathetic (SNS) and parasympathetic (PNS) 
nervous systems.  These two systems innervate the same target organs, and either 
cooperate or contrast with one another to produce different effects on the body49.  The 
SNS and PNS are not opposites; rather, they form a web of complex interactions 
responsible for maintaining proper balance between the two systems44.  The SNS and 
PNS can, depending on the target organ, be either stimulatory or inhibitory and act 
simultaneously to produce an effect49.   
The SNS is often referred to as the ‘fight or flight’ division of the ANS.  It adapts the 
body for more physically active situations, and is usually employed in states of arousal, 
anger, danger, fear, etc49.  In the heart, stimulation of the SNS causes an increase in heart 
rate and force of contraction. 
The PNS is often referred to as the ‘rest or digest’ division of the ANS.  It is used 
predominantly in non-physically active situations such as in the process of digestion.  In 
the heart, stimulation of the PNS causes a decrease in heart rate and force of contraction 
and is of stronger influence than the SNS at rest.  PNS signals to the heart travel through 
the vagus nerve, one of the cranial nerves.  The brain receives signals from sensory 
receptors about conditions of the heart such as heart rate before signals are sent to carry 
out necessary responses.  In the PNS, long preganglionic nerve fibers carry the signal 
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from the brain and synapse with short postganglionic nerves.  At the synapse, 
acetylcholine is released and binds to nicotinic receptors on postganglionic fibers.  The 
signal travels through these fibers and reaches the target organ.  Here, acetylcholine is 
released again, this time binding to muscarinic receptors on cardiomyocytes49.       
 
1.4  Autonomic Nervous System and Heart Failure 
An imbalance of the ANS is a defined characteristic in the progression of HF1.  
Because of this, it is important to be able to evaluate autonomic activity in cardiovascular 
disease.  Research concludes that increase in SNS activity and decrease in PNS activity 
are related to an increased risk of death in cardiovascular disease29.  However, it is 
difficult to quantify ANS activity because of its complexity29.  Therefore, exploring 
various markers that reflect autonomic activity remains a vital area of research.   
The SNS increases heart rate and force of contraction in a non-diseased state.  It is 
activated when norepinephrine (NE) binds to beta-adrenergic receptors (β-AR) on 
cardiomyocyte plasma membranes (signaling pathway depicted in Figure 3).  These β-
ARs interact with heterotrimeric Gs proteins that stimulate adenylyl cyclase.  This 
effector molecule dissociates ATP into cyclic-AMP to bind protein kinase A (PKA).  
PKA phosphorylates L-type Ca++ channels, RYRs, PLB, and troponin I, which causes an 
increase of Ca++ movement.  Increase in Ca++ ultimately causes a positive inotropic and 
chronotropic effect on the heart. 
In HF, the SNS is overactivated.  This system first acts to compensate for declining 
cardiac function, yet long-term activation decompensates cardiac function55.  A notable  
 8
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Figure 3.  β-AR Signaling Pathway.  Agonists, such as norepinephrine bind 
to β-ARs on cardiac myocytes which stimulates Gs proteins to active 
adenylyl cyclase (AC).  Through downstream signaling, proteins that 
increase Ca++ movement within the cell are activated by phosphorylation.  
An increase in Ca++ movement results in a positive inotropic and 
chronotropic effect. 
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and well-studied feature of the SNS in HF is alterations in β-AR density.  It has been 
found that β-AR density is significantly downregulated in the failing heart4,13,55.  
Specifically, the ratio of β-AR subtypes, β1 and β2, drop from approximately 75:25 in a 
non-diseased state to 60:40 during failure4.  β1-AR population decreases while β2 does 
not significantly change4.  β-AR downregulation is the result of high concentrations of 
NE leading to desensitization of the receptor.  What has been developed with the 20+ 
years of research on β-ARs are drug therapies targeting and blocking these SNS receptors 
from activating signaling pathways.  These drugs, commonly called β-blockers, are now 
universally used to decrease sympathetic overactivation in the failing heart.  In studying 
LVAD support and the SNS, β-AR density has been shown to be restored through LVAD 
support with densities closely mimicking non-failing results42. 
The role of the PNS in HF is not as clear.  It is established that autonomic dysfunction 
in HF is related to overactivation of the SNS and attenuation of the PNS.  To examine 
PNS control, vagal nerve studies have been an area of recent research.  Stimulation of the 
vagus nerve has improved cardiac function and increased survival in various models of 
HF33,51,54,61.  This occurs primarily because acetylcholine released from the vagus 
interacts with cholinergic receptors on cardiomyocytes and inflammatory cells54.  PNS 
regulation of heart rate is increased, along with inhibiting release of inflammatory 
cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1)54.  With these 
changes upon vagal stimulation, autonomic balance improves and inflammatory 
responses are supressed61.  Vagal nerve stimulation is shown to be of potential 
therapeutic benefit and is one way of targeting the PNS in HF.   
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Because SNS activity was studied using the target membrane receptor on 
cardiomyocytes, another way to examine PNS activity is to study the target receptor of 
the PNS:  muscarinic receptors.  Up to this point, attempts to study the PNS in HF this 
way have led to conflicting results, thereby no definitive conclusions have been drawn 
1,3,19,32,56. 
 
1.5  Muscarinic Receptors 
Muscarinic receptors belong to the family of receptors known as g-protein coupled 
receptors (GPCRs).  GPCRs are one of the most abundant and diverse of protein families, 
and the most common type of cardiac receptor27,47.  There are an estimated six major 
classes of GPCRs, which are thought to be of early evolutionary origin due to their 
presence in bacteria and yeast27.  The ANS utilizes adrenergic and muscarinic cholinergic 
receptors to maintain homeostasis in the heart and cardiovascular system47.  Muscarinic 
receptors are expressed in a variety of cells and are further broken down into five specific 
subtypes5,16.  These subtypes are named M1-M5, based on the order of their discovery16.  
Muscarinic receptors are composed of seven transmembrane alpha helices, with an 
extracellular N-terminus and intracellular C-terminus27.  These seven hydrophobic 
transmembrane domains are connected by three extracellular and three intracellular 
hydrophilic loops16.  M1-M5 share 90% of their amino acid sequences within their 
hydrophobic domains and differ the greatest in their loop and tail regions16.  In the heart, 
M2 is thought to be the most predominant, and at one time, was thought to be the only 
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subtype present on cardiomyocytes5,8,45.  More recent studies, however, have suggested 
multiple subtypes existing in mammalian heart tissue52,58.   
 Muscarinic receptor subtypes differ in signaling pathways.  All GPCRs rely on an 
extracellular stimulus to activate intracellular signals via interaction of heterotrimeric G 
proteins with the receptors’ intracellular loops27.  In basic signal transduction, a ligand 
binds to its appropriate receptor to stimulate a conformational change of the receptor.  
This change in conformation leads to activation of an associated heterotrimeric G protein, 
allowing for the G protein’s α subunit to dissociate from its β and γ subunits.  The G 
protein subunits activate and amplify signals within the cell by altering activity of an 
effector molecule.  The activities of the effectors control production of second messenger 
molecules leading to a variety of downstream signaling pathway activation16,27,47.  
Although all muscarinic receptors use this basic signal transduction mechanism, the 
subtypes differ in G proteins, effectors, and second messengers, leading to different 
cellular responses.  The even-numbered muscarinic receptor subtypes, M2 and M4, couple 
to a Gi protein, while M1, M3, and M5 interact with a Gq protein.  For all five subtypes, 
initial conformational change occurs when acetylcholine binds to the receptor.  Illustrated 
in Figure 4, M2 and M4, upon activation of Gi, inhibit adenylyl cyclase (AC) activity, 
leading to a reduction in intracellular levels of cAMP16.  This inhibits cyclic AMP-
dependent kinases (PKA) from phosphorylating proteins such as L-type Ca++ channel, 
RYRs, PLB, and troponin I, causing a decrease in movement of Ca++.  This pathway 
antagonizes the SNS signaling pathway and is active after stimulation of the SNS.  Even-
numbered muscarinic receptors also directly open K+ channels on the plasma membrane,  
 12
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Figure 4.  Even-Numbered (M2/M4) Muscarinic Receptor Signaling Pathway.  
Agonists, such as acetylcholine (ACh), bind to muscarinic receptors on cardiac 
myocytes which activate Gi proteins.  Gi proteins antagonize the β-AR signaling 
pathway by inhibiting AC from increasing intracellular cAMP levels.  This results 
in a decrease in Ca++ movement within the cell which produces a negative 
inotropic and chronotropic effect on the heart. 
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turning off the electrical signals caused by depolarization, reducing contractility, however 
evidence in ventricular tissue is lacking25.  M1, M3, and M5, upon activation of Gq, 
activate phospholipase C (PLC) (signaling pathway depicted in Figure 5).  PLC 
hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate 
(IP3) and diacylglycerol (DAG)5,16.  DAG stimulates protein kinase C (PKC) while IP3 
releases Ca++ from the SR, leading to an increase in heart rate and force of contraction25.  
Because the M2 receptor subtype is thought to exert greater influence than the other 
subtypes on cardiomyocytes, the predominant effect of muscarinic stimulation to the 
heart is inhibitory. 
 
1.6  Research Goal 
The goal of this project is to study the role of the PNS in human HF.  The hypothesis 
that the PNS is dysregulated in human HF will be tested using muscarinic receptor 
density as a measurable variant of PNS activity.  Total muscarinic receptor densities will 
be measured using a modified radioligand binding assay protocol, while muscarinic 
subtypes will be measured using a time-dependent competition binding assay.  With these 
established techniques, muscarinic receptor densities in non-failing and failing human 
heart samples will be analyzed.  Muscarinic receptor densities in failing tissue samples 
from patients who had LVAD support will also be studied.  This population will allow us 
to explore the restoring capabilities of LVADs on the PNS.  Once densities in nonfailing, 
failing, and failing + LVAD support heart tissue samples are measured, muscle function 
analyses will be performed.  Muscle function experiments will provide insight on the  
 14
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  Odd-Numbered (M1/M3/M5) Muscarinic Receptor Signaling Pathway.  
to odd-numbered muscarinic receptors on 
yocytes which stimulate Gq proteins.  Gq proteins activate phospholipase 
2 into IP3 and DAG.  DAG activates a downstream 
pathway by PKC while IP3 directly activates Ca++-channels on the SR, leading to 
++ release.  This increase in Ca++ results in a positive inotropic and 
chronotropic effect.  (Abbreviations:  PIP2 = phosphatidylinositol 4,5-
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inotropic response of fresh trabecular muscle upon acetylcholine and isoproterenol 
stimulation.  Results from these experiments will be used to compare contractility 
changes to receptor density changes in each population.  Conclusions found through the 
data analysis may provide for a novel approach in tackling human heart failure, leading to 
better and more effective treatment options. 
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CHAPTER II 
METHODS 
 
 
2.1  Human Hearts 
 Human hearts were obtained from a patient population only after IRB approval and 
patient consent.  Left ventricular (LV) tissue was obtained from patients with non-failing 
hearts, failing hearts, and failing hearts which had been supported by an LVAD prior to 
transplant.  Non-failing and failing samples were used to compare the effects of heart 
failure on muscarinic receptor density.  In anticipation of finding differences, a second 
failing group was studied to explore the recovery of muscarinic receptors by mechanical 
unloading in patients with an LVAD (failing + LVAD).  Non-failing hearts were obtained 
from unmatched organ donors whose hearts were unsuitable for transplantation.  Failing 
and failing + LVAD groups were the explanted hearts of cardiac transplant recipients at 
Cleveland Clinic.  Inclusion criteria for donor sample selection were males and females, 
between 40-65 years of age.  Since left ventricular ejection fractions above 50% 
demonstrate normal cardiac function, only donor hearts with ejection fractions ≥ 50% 
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were included.  Inclusion criteria for failing and failing + LVAD samples were males and 
females, between 40-65 years of age, with an ejection fraction <35%.  Exclusion criteria 
included pacemakers because of the unknown effect pacing may have on autonomic 
nervous system regulation.  Samples were also excluded if patients were on drugs with 
potential muscarinic interactions.  These included sotalol, amiodarone (for non-failing 
and failing samples only), disopyramide, quinidine, and atropine.  These drugs were 
excluded based on previously reported drug/receptor interactions9,11,38,39,41.  Right atrial 
tissue was also obtained from heart failure patients undergoing cardiac transplantation 
and a piece of de-identified brain tissue was acquired from the Department of Pathology 
at CC.  Both served as positive controls. 
 For muscle function analyses, fresh trabecular muscles were taken from non-failing 
and failing patients immediately following acquirement of tissue from operating rooms.  
Non-failing left ventricular tissue came from patients with hypertrophic cardiomyopathy 
(HOCM) and failing left ventricular tissue came from explanted hearts of cardiac 
transplant recipients at Cleveland Clinic.  Non-failing tissue included both males and 
females, aged between 41-74 years, and with ejection fractions >50%.  Failing tissue 
included both males and females, between 46-68 years of age, with ejection fractions 
below 35%. 
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2.2  Membrane Preparation 
 Frozen human heart samples were broken into pieces weighing 2.0-2.2 g and placed 
into Buffer A [composition: 10mM (4-(2-hydroxyethyl)-1-Piperazineethanesulfonic acid 
(HEPES), 5mM Ethylene glycol tetraacetic acid (EGTA), 12.5mM Magnesium Chloride 
(MgCl2), 250mM Sucrose, 10mg/mL Leupeptin, 20µg/mL 
Phenylmethanesulfonylfluoride (PMSF), 20µg/mL Bacitracin, 20µg/mL Benzamidine].  
Samples were homogenized in 3 second bursts with 5 second rests on ice until no chunks 
of tissue remained.  Homogenates were centrifuged at 300 x g for 5 minutes at 4ºC to 
pellet out heavier organelles such as nuclei and mitochondria.  Supernatants (containing 
lighter cytosolic fragments such as actin/myosin filaments and membrane fragments) 
were incubated in 0.5M KCl solution for 15 minutes at 4ºC to destroy the myofilaments 
in the supernatant.  Suspensions were centrifuged at 40,000 x g for 15 minutes at 4ºC to 
pellet the membrane fraction.  The supernatant was discarded and pellets were added to 
buffer B, a non-sucrose containing buffer [composition:  20mM HEPES, 5mM EGTA, 
12.5mM MgCl2, 100mM NaCl; and 20µg/mL each of Leupeptin, PMSF, Bacitracin, and 
Benzamidine)].  In buffer B, pellets were Dounce homogenized (10 times slowly with a 
loose plunger followed by 10 times slowly with a tight plunger) to refine the membrane 
fraction.  Once each sample was homogenized, preparations were centrifuged to re-pellet 
membrane preparations (40,000 x g for 15 minutes at 4ºC).  Pellets underwent a second 
series of homogenization to further refine the membranes.  Preparations were centrifuged 
at 40,000 x g for 15 minutes at 4ºC.  Final pellets were added to buffer B + 10% glycerol 
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to help preserve the membranes upon storage.  Pellets were resuspended using a 
motorized homogenizer until they were fully suspended.  Aliquots were stored at -80ºC. 
 
2.3  Determination of Protein Concentration 
 Lowry protein assays were performed on membrane preparations to determine total 
protein concentrations.  Standards containing known concentrations (0.0, 0.5, 1.0, 2.0, 
3.0, 4.0 mg/mL) of bovine serum albumin (BSA) were added to a 96 well plate, in 
triplicate.  1:2 dilutions of membrane preparations were also added in triplicate to the 96 
well plates.  Reagent A, a solution that recognizes peptide bonds and binds to all protein, 
was added to each standard and sample.  Reagent B, a solution that recognizes reagent A 
and, upon binding, produces a color change, was then added to each well.  The standards 
and samples were incubated for 15 minutes at room temperature.  The absorbance was 
read at 750nm.  The known concentrations of BSA were used to generate a standard 
concentration curve from each standard’s measured absorbance and this was then used to 
determine the unknown sample concentrations. 
 
2.4  Membrane Titer Assay 
 A radioligand binding assay was used to measure total muscarinic receptor density and 
affinity.  Before beginning these experiments, the amount of membrane necessary to 
attain 10% specific binding was determined using a membrane titer assay. 
 In a membrane titer assay, a non-selective radiolabeled antagonist (3H-Quinuclidinyl 
benzilate) is added to membrane to determine total binding to muscarinic receptors.  Non-
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specific binding is determined by adding 3H-QNB in the presence of a second non-
selective and non-labeled muscarinic receptor antagonist (atropine).  Atropine is added in 
a high concentration in order to ensure atropine binding to the muscarinic receptor, such 
that any radioactivity remaining is due to 3H-QNB binding to something other than 
receptor.  By subtracting non-specific binding from total binding, specific binding can 
then be determined.  3H-QNB is also measured in the absence of membrane to ascertain 
total counts of radioactivity.  Final calculations are performed to determine the amount of 
membrane needed for specific binding to equal 10% of total counts of  radioactivity.  
Details for this assay are as listed below. 
 All steps prior to incubation were performed on ice.  Six 12x75mm polypropylene 
tubes were used for each heart sample:  three to measure total binding in triplicate and 
three to measure non-specific binding, also in triplicate.  A buffer containing 20mM 
HEPES, 15mM EGTA, 1.25mM MgCl2 (HEM) and 0.1% BSA was added to all total 
binding and non-specific binding tubes and was used to prepare 3H-QNB, atropine, and 
membrane. 
 For this assay a theoretical Kd taken from the literature was used58.  250pM of 3H-
QNB was added to all total binding, non-specific binding, and total count tubes.  
Atropine (non-selective, non-labeled) was added to the non-specific binding tubes to 
achieve a 1µM antagonist concentration. 
 Membrane preparations were added last.  Frozen aliquots of tissue samples were 
thawed on ice and diluted to 25µg protein per tube.  Preparations were added to total and 
non-specific binding tubes.   
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 Tubes (with a final volume of 250µL) were mixed on a Vortex mixer and placed in a 
shaking water bath for 1 hour at 37ºC.  After incubation, preparations were harvested 
onto GF/C filter paper, and washed five times with cold HEM.  Filters were cut out and 
placed in 7mL scintillation vials and set in a 42ºC oven to dry.  Once dried, 5mL of 
Cytoscint ES scintillation fluid was added to each vial.  Vials were capped, mixed, and 
then wiped with a dryer sheet (to avoid artificially high values due to static discharge).  
Vials were read in a scintillation counter for two minutes each.      
 
2.5  Measuring Total Muscarinic Receptor Density and Affinity  
 A radioligand binding assay was used to measure total muscarinic receptor density and 
Kd.  In this assay, multiple doses of 3H-QNB were added to samples to generate a 
saturation curve and Lineweaver-Burk plot.  
 Forty-eight 12x75mm polypropylene tubes were used per heart.  For each heart, three 
tubes were used to measure total binding and three were used to measure non-specific 
binding (run in triplicate) at each dose of radioactivity.  Eight doses of radioactivity were 
utilized in this assay.   
 Eight differing doses of 3H-QNB were made.  The highest dose (1500pM) of 
radioactivity was prepared and the seven other doses were serial diluted from the highest 
dose to achieve final concentrations [concentrations in pM:  11, 27, 68, 135, 270, 540, 
900, 1500].  Buffer and atropine were added as described in Section 2.4. 
 Membrane preparations were added last.  Frozen aliquots of tissue samples were 
thawed on ice and diluted to amounts determined by the membrane titer assay.   
 22
 Tubes were mixed and placed in a shaking water bath for 1 hour at 37ºC.  After 1 
hour, preparations were harvested onto GF/C filter paper, dried, and read as described in 
Section 2.4. 
 Results generated a saturation curve measuring concentration of radioactivity to 
amount of binding.  A Lineweaver-Burk plot was created by plotting binding (pmol/mg) 
to the ratio of bound vs. free radioactivity.  The x-intercept of this plot was equivalent to 
the Bmax (density) of the sample and the slope equals the Kd.  An example of a 
saturation curve and Lineweaver-Burk plot is depicted in Figure 6. 
 
2.6  Measuring Muscarinic Receptor Subtypes  
 Muscarinic receptor subtypes were measured using a time-equilibrium binding assay.  
In this assay, one concentration of radioactivity was used and changes in binding were 
measured over a two hour time course in the presence of the selective non-labeled 
antagonist for each subtype.  Saturation curves were generated to determine the fraction 
of each subtype.  An example is shown in Figure 7. 
 One hundred and eighty 12x75mm polypropylene tubes were used per heart.  Thirty 
tubes were used for each condition (total binding, nonspecific binding, antagonist binding 
for M1, M2, M3, and M4).  Buffer and atropine was added as described in Section 2.4.  
After preliminary studies and a literature search, Ki’s were determined for the project.  
To measure subtypes, non-labeled subtype-selective antagonists were used [in 1mM:  M1 
– Pirenzepine, M2 – Methoctramine, M3 – p-Fluoro-hexahydrosila-difenidol (pf-HHSiD), 
M4 – Tropicamide].  No current subtype selective antagonist is available for M5 and this 
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Figure 6.  Saturation Curve (Top) and Lineweaver-Burk Plot (Bottom).  
Radioligand binding assays generate a saturation curve and Lineweave-Burk plot 
to determine density and Kd of samples.  The Lineweaver-Burk plot is a linear 
interpretation where specific binding is plotted against the ratio of bound to free 
radioactivity.  The x-intercept of a Lineweaver-Burk plot is the Bmax, or density 
of the receptor of interest.  The Kd is interpreted by the slope of the line.  
(Abbreviations:  B = Specific Binding, B/F = Specific Binding divided by the 
Concentration of Free Radioligand)
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 Figure 7.  Saturation Curve for the Time-Dependent Competition Binding 
Assay.  Percent binding of muscarinic subtypes were found by generating 
best-fit lines (shown on the right) from saturation curves (shown on the left).  
The values at the 2 hour time-point were fractioned from specific binding to 
determine results. 
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receptor subtype was therefore not measured in this study.  Each antagonist was added at 
its established Ki value.  Ki values were as follows (in M):  Pirenzepine = 4.66 x 10-9, 
Methoctramine = 6.18 x 10-8  pf-HHSiD = 1.92 x 10-8, Tropicamide = 2.82 x 10-8. 
 Holding radioactivity at 150pM per tube for all total binding, non-specific binding, 
and total count tubes, membrane (amount determined from membrane titer assay) was 
incubated in the presence of the selective antagonists. Tubes were mixed.  Incubations 
were run in a shaking water bath at 37ºC.  Tubes were incubated at ten different time 
points (in minutes:  0, 10, 20, 30, 45, 60, 75, 90, 105, 120).  Once complete, incubations 
were halted by placing tubes back into an ice water bath.  Preparations were harvested, 
dried, and read as described in Section 2.4. 
 
2.7  Muscle Function Experiments 
 Fresh trabecular muscles from non-failing, failing, and failing + LVAD tissues were 
used in this experiment.  Tissue samples were collected from the operating room and 
placed in cold cardioplegia solution.  Once in the lab, tissue samples were placed in an 
oxygenated petri dish filled with Krebs-Henseleit buffer (KHR) [composition in nM:  100 
NaCl, 4.0 KCl, 1.5 MgSO4*7H2O, 20.0 NaHCO3, 1.5 NaH2PO4, 20.0 Na-Acetate, 10.0 
Glucose, 0.1 Ascorbic Acid, 2.5 CaCl2, and 5.0 IU Insulin].  Up to 7 long, slender 
cylindrical muscles with a cross sectional area less than 1.1 mm2 were dissected from the 
tissue.  Each muscle was secured between two o-rings and transferred to the muscle 
experiment set-up. 
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 A typical muscle experiment set-up is depicted in Figure 8.  Each muscle is 
surrounded by a tissue bath filled with oxygenated KHR continuously heated at 37ºC.  
Inside the bath, muscles are hung by two hooks and are in direct contact with platinum 
electrodes.  These platinum wires send electrical stimuli (1Hz every 5msec) to the muscle 
via a stimulator.  The stimulator controls the frequency, duration, and amount of voltage 
of each stimulus sent to the muscle.  After the muscle is stimulated, the muscle produces 
tension in response to the stimulus, which is sensed by a force transducer.  This sends the 
amount of force generated by the muscle to an amplifier which amplifies and conditions 
the signal and sends it to LabChart 7 Pro, a software program.  Once on data acquisition 
software, results can be analyzed for six different contractile parameters.  Contractile 
parameters analyzed are shown in Figure 9.  These parameters include resting tension 
(RT), developed tension (DT), time to peak tension (TPT), time to half relaxation (THR), 
peak rate of tension rise (+dT/dt), and peak rate of tension fall (-dT/dt).  RT is the tension 
produced by the muscle at rest and DT is the force produced by the muscle during 
contraction.  TPT is the time it takes for the muscle to reach its peak of contraction and 
THR is the time it takes for the muscle to get from the peak of contraction to the halfway 
point of relaxation.  dT/dt is the maximal rate of contraction (+dT/dt) or relaxation (-
dT/dt).   
  Once hung on the set-up, each muscle remained in the bath for one hour without 
electrical stimulation.  Muscles were then stimulated repeatedly for two minutes at 10V 
to reach a steady state of contraction.  The threshold voltage was found by lowering 
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Figure 8.  Typical muscle bath set-up.  Each dissected muscle is secured 
between two o-rings and hung across a pair of platinum electrodes.  
Muscle baths are then lifted to surround the muscle with circulating, 
oxygenated Krebs-Henseleit buffer heated to 37ºC.   
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Figure 9.  Typical muscle contraction with contractile parameters.  
From an individual muscle contraction, determination of six 
contractile parameters are used to establish functionality, including 
resting tension (RT), developed tension (DT), time to peak tension 
(TPT), and time to half relaxation (THR).  Peak rate of tension rise 
(+dT/dt) and peak rate of tension fall (-dT/dt) (not shown) are 
established at the steepest slope of the line leading to the peak of 
contraction and the steepest slope of the line leading back to RT. 
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voltage to 1V and increasing by 0.2V until the muscle began contracting.  Upon 
contraction, voltage was increased by 20% which set the voltage for the remainder of the 
experiment. 
 A length-tension curve (LTC) was performed once muscles were contracting steadily 
at threshold voltage.  Muscles were stretched by 0.1 mm.  After one minute at the new 
length, DT and RT were recorded.  These steps were repeated until DT stopped 
increasing upon stretch of the muscle to reach Lmax (length associated with greatest 
muscle contraction).  Setting each muscle to its Lmax allowed for individual muscles to 
be compared to others.  Once each reached Lmax, muscles were left for 30 minutes to 
stabilize under these new conditions.  After 30 minutes, muscles with DT ≥ 0.20g were 
used for the experimental protocol. 
 Muscles were divided into two groups:  those that received Acetylcholine (Ach) and 
those that served as time controls.  A dose-response curve to Ach was performed.  1nM 
Ach was added only to the experiment group of muscles.  After ten minutes, 10nM Ach 
was added.  This series was repeated until six doses of Ach was added (1, 10, and 
100nM, followed by 1, 10, and 100µM).  After the last dose was added followed by the 
10 minute rest, all muscles received 1µM isoproterenol. 
 Once the experimental protocol was complete, muscles were removed from KHR so 
the length between their o-rings could be measured.  Once recorded, muscles were cut 
from the o-rings and placed in bibulous paper to dry.  After drying for 15 minutes, 
individual muscles were weighed, so cross-sectional area (XSA) could be calculated.  
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XSA = (weight of muscle / length of muscle) ÷ density of muscle.  RT, DT, +dT/dt, and –
dT/dt were divided by XSA to normalize for muscle size. 
 Data recorded throughout the experiment was analyzed in order to draw conclusions. 
 
2.8  Statistical Analysis 
 Total muscarinic receptor density and the percent of muscarinic receptor subtypes in 
non-failing, failing, and failing+LVAD tissue were analyzed using a one-way analysis of 
variance (ANOVA) and a Newman-Keuls post-hoc comparison test.  Diagnoses (dilated 
cardiomyopathy versus ischemic cardiomyopathy) in failing and failing+LVAD groups 
were analyzed by a Kruskal-Wallis test followed by the Dunn’s Multiple Comparison 
test.  The Kruskal-Wallis test and Dunn’s Multiple Comparison test was also used to 
determine total muscarinic receptor Kd changes between groups.  Data is expressed as 
mean ± SEM and significant differences were determined only when p < 0.05. 
 Baseline parameters in the muscle function experiments were analyzed using an 
unpaired t-test if the parameter passed a normality test or a Mann Whitney test if the 
parameter did not pass a normality test.  Dose-response curves were analyzed by a two-
way ANOVA followed by the Bonferroni post-test.  A two-way ANOVA and Bonferroni 
post-test was also used to determine the response of muscles upon the addition of 
isoproterenol.  Data is expressed as the mean ± SEM for baseline parameters, mean 
percent change from baseline for dose-response curves, and mean percent change from 
the last dose of acetylcholine for isoproterenol data.  Significant differences were 
determined only when p < 0.05. 
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CHAPTER III 
RESULTS 
 
 
3.1  Total Muscarinic Receptor Density and Affinity 
 Table I shows the patient population used to measure muscarinic receptors (all = total; 
highlighted in grey = subtypes; Table I on page 32, description of Table I on page 33).  
Patients of both sexes were included in the study and sample groups were chosen to have 
a similar age (in mean ± SD; NF = 49 ± 5, F = 51 ± 5, and F+LVAD = 52 ± 8).  Because 
ejection fractions ≥ 50% are a marker of normal cardiac function, NF samples only with 
ejection fractions ≥ 50% were included.  F and F+LVAD samples had ejection fractions ≤ 
50%.  Exclusion criteria was also considered, therefore patients on pacemakers or on 
drugs with potential muscarinic interactions were excluded from the study.  Common 
medications taken by the patient population are included in Table I, with patients most 
commonly on β-blockers, angiotensin converting enzyme (ACE) inhibitors, and 
inotropes.  Sixty-one total left ventricular samples were used to measure total muscarinic  
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Patient # Diagnosis Age Sex Ejection Fraction Medications
1 NF 60 F 65 DOB, NE
2 NF 54 F N/A NE
3 NF 42 M N/A DOP
4 NF 53 F 50 DOP, EN
5 NF 44 M 75-80 DOP
6 NF 50 M 60 DOB
7 NF 44 F 55-60 DOP, NE
8 NF 50 M 70 N/A
9 NF 50 F 65-70 DOP, NE
10 NF 48 F 50-55 DOP
11 NF 55 F 60 DOP
12 NF 46 F 70 NE
13 NF 56 F 65 DOP, EN
14 NF 47 F 50 DOP
15 NF 40 M 60 DOP
16 F-DCM 40 M 10 NE
17 F-DCM 48 F 15 CARV, DIG, LIS
18 F-DCM 54 M 15 LOS
19 F-DCM 56 F 25 CARV, LIS, MIL
20 F-DCM 47 M 30 LIS, MET
21 F-DCM 45 M 10 LIS, MIL
22 F-DCM 49 F 30 N/A
23 F-DCM 53 F 15 CARV, DIG, DOB, DOP, MIL, NE
24 F-DCM 46 M 15 CARV
25 F-DCM 53 F 20 CARV, MIL
26 F-DCM 41 M 10 CARV
27 F-DCM 50 M 10 DOP
28 F-DCM 52 F 10 CARV, DIG
29 F-DCM 45 F 15 CARV
30 F-DCM 52 M 25 DIG, LIS, MET
31 F-ICM 56 F 15 LIS, MET
32 F-ICM 60 F 25 CARV
33 F-ICM 52 M 24 CARV
34 F-ICM 58 M 15 MET, MIL
35 F-ICM 53 M 35 CARV, DIG, VAL
36 F-ICM 52 M 15 DIG, MIL
37 F-ICM 56 M 15 CARV, MIL
38 F-ICM 43 F 30 CARV, MIS
39 F-ICM 53 M 15 MIL
40 F-ICM 55 F 15-20 CARV
41 F-ICM 48 M 20 LIS
42 F-ICM 54 F 10 DIG
43 F-ICM 58 F 35 N/A
44 F-ICM 58 M 20 CARV
45 F-ICM 55 F 20 DIG
46 F+LVAD 42 M 15 EN
47 F+LVAD 50 M 10 N/A
48 F+LVAD 43 M 15 DIG
49 F+LVAD 59 M 10 N/A
50 F+LVAD 54 M 15 DOB, DOP, EPI, NE
51 F+LVAD 53 F 10 N/A
52 F+LVAD 51 M 15 DOB
53 F+LVAD 44 M 10 DOB
54 F+LVAD 43 M N/A MET
55 F+LVAD 39 M 10 CARV, DIG, DOP
56 F+LVAD 62 M 50 DIG
57 F+LVAD 62 F 15 N/A
58 F+LVAD 54 M 20 CARV, LIS
59 F+LVAD 65 M 25 N/A
60 F+LVAD 65 M 20 CARV, LIS
61 F+LVAD 49 M 10 LIS, MET
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Table I.   Characteristics of Patients Used to Measure Total and Subtyped Muscarinic Receptors.  Sixty-one human left 
ventricular samples were used to measure total muscarinic 
receptor density and 36 of these samples (highlighted in grey) 
were also used to measure the percent of M1-M4 receptor 
subtypes.  Patients in each diagnosis were chosen with similar 
ages and both males and females were used in the study.  Ejection 
fractions in NF tissue needed to be ≥ 50% and in F and F+LVAD 
tissue ≤ 35% to be included in the study.  Common medications 
are also listed.  (Abbreviations:  DOB = Dobutamine, NE = 
Norepinephrine, DOP = Dopamine, EN = Enalapril, CARV = 
Carvedilol, DIG = Digoxin, LIS = Lisinopril, LOS = Losartan, 
MIL = Milrinone, MET = Metoprolol, EPI = Epinephrine, VAL = 
Valsartan) 
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receptor density and 36 of these samples were also used to measure the percents of 
muscarinic receptor subtypes. 
 Before measuring total muscarinic receptor density on all 61 left ventricular samples, 
positive controls were measured to ensure valid experimental technique.  It is established 
that there are a more dense population of muscarinic receptors in atrial tissue compared to 
ventricular tissue and there are even greater densities in the brain than in the atria or 
ventricles22,44.  Using my established radioligand binding assay protocol, I measured 
receptor densities on left ventricular and right atrial tissue (n=3 per group) from the same 
hearts and from one piece of un-identified brain tissue.  Figure 10 shows that the lowest 
muscarinic receptor density was measured in the three left ventricular samples (332.70 ± 
35.90 fmol/mg).  The three hearts had a higher density in the right atrium, with densities 
of 571.70 ± 93.78 fmol/mg.  The brain tissue had receptor densities of 1029 fmol/mg 
protein.  The positive controls mimicking data in the literature supported the 
experimental protocol we established, therefore the 61 project samples could be 
successfully measured. 
 Figure 11 shows the results of the radioligand binding assays on the 61 project 
samples.  The 15 NF samples were found to have receptor densities of 194.10 ± 17.27, F 
samples 275.80 ± 11.89, and F+LVAD samples 315.80 ± 23.94 (all in fmol/mg protein).  
The F group was found to be significantly increased compared to control group (p<0.01) 
and F+LVAD group was even more significantly increased compared to control 
(p<0.001).  Because the F and F+LVAD groups contained samples with a diagnosis of  
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 Figure 10.  Positive Control Experiment.  Right atrial and left 
ventricular (LV) tissue was taken from the same 3 hearts (from 
patients undergoing cardiac transplantation) and one piece of 
un-identified brain tissue was acquired from pathology to 
measure total muscarinic receptor densities. 
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 Figure 11.  Total Muscarinic Receptor Density.  A 1-way 
ANOVA detected a significant increase in total muscarinic 
receptor density in F samples compared to control (p<0.01) and 
an even more significant increase in receptor density in 
F+LVAD samples versus control (p<0.001). 
 
 
 
 
 
 
 37
  
 
 
 
F-DCM F-ICM L-DCM L-ICM
0
100
200
300
400
n=14 n=7 n=9n=15
R
ec
ep
to
r D
en
sit
y
(fm
ol
/m
g 
pr
ot
ein
)
 Figure 12.  Relationship of Muscarinic Receptor Densities to Patient 
Diagnosis.  Total muscarinic receptor density comparisons were made 
between DCM and ICM diagnoses in F patients and patients with 
LVAD support.  A statistical analysis was performed and found no 
significant differences in density between etiologies (p=0.698).  L-
DCM and L-ICM densities were also unchanged between groups 
(p=0.974).  (Abbreviations:  DCM = Dilated Cardiomyopathy;  ICM = 
Ischemic Cardiomyopathy;  L = F+LVAD group) 
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both DCM and ICM, I wanted to see if various diagnoses of HF resulted in different 
muscarinic receptor densities.  As shown in Figure 12, when separating the F group into 
F-DCM and F-ICM, receptor densities were unchanged (263.90 ± 20.98 versus 274.40 ± 
16.80).  Densities were also not significantly different when the F+LVAD group was 
separated into diagnoses (316.70 ± 38.03 versus 315.00 ± 32.66).  Groups were further 
divided into male versus female to see if gender had an effect on muscarinic receptor 
densities (F+LVAD group was not analyzed this way due to the uneven distribution of 
males and females).  A t-test was run to compare males to females in the NF group and 
males to females in the F group, as shown in Figure 13.  No significant differences were 
found in the NF group, with females (n=10) having densities of 180.3 ± 17.9 fmol/mg 
protein and males (n=5) with densities of 221.9 ± 37.4 fmol/mg protein.  The F group 
also showed no significant changes in receptor densities, with the mean density in 
females (n=13) 289.9 ± 18.8 fmol/mg and males (n=16) 252.6 ± 17.7 fmol/mg protein.    
 LVADs, although all implantable pumps that hemodynamically unload the heart, have 
developed into different types and are implanted for varying amounts of time from 
patient to patient.  Because of these factors, the type of LVAD was compared to see if 
muscarinic receptor densities changed from LVAD type.  Figure 14 compares muscarinic 
receptor densities in different LVAD types.  A Mann-Whitney analysis was performed 
and found no significant changes in receptor density between pulsatile (284.5 ± 33.1 
fmol/mg) and non-pulsatile (334.5 ± 32.6 fmol/mg) LVADs.  Figure 15 compares the 
duration of time patients were supported with an LVAD to their found muscarinic  
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 Figure 13.  Gender Comparisons Between NF and F 
Muscarinic Receptor Densities.  NF and F muscarinic receptor 
densities were separated into male (M) and female (F) groups to 
see if differences in muscarinic receptor densities occurred with 
gender differences.  No significant changes in densities were 
detected by t-test analysis for the NF (p=0.271) and F (p=0.162) 
groups.  
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Figure 14.  Total Muscarinic Receptor Densities in 
Different LVAD Types.  Two types of LVADs, pulsatile 
and non-pulsatile, were found to have no significant effect 
on muscarinic receptor densities through a Mann-Whitney 
statistical analysis (p=0.368). 
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Figure 15.  Relationship between duration of LVAD Support 
and Total Muscarinic Receptor Density.  The amount of time 
patients were on LVAD support was compared to their found 
muscarinic receptor densities.  No significant correlation was 
detected between the days on LVAD support to receptor density 
(p=0.260). 
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 Figure 16.  Muscarinic Receptor Kd.  Kd values were found in 
the radioligand binding assays.  A 1-way ANOVA found no 
significant change in Kd from NF to F samples.  A significant 
increase in Kd was found in the F+LVAD group versus control 
(p<0.001).  
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receptor densities.  Statistical analysis found no significant correlation between the days 
of LVAD support and receptor densities.    
 The radioligand binding assays measured total muscarinic receptor density as well as 
receptor Kd.  The Kds found for the three groups are depicted in Figure 16.  No 
significant differences were found when comparing NF and F groups, with Kds of 220.40 
± 15.88 pM in F versus 161.10 ± 14.54 pM in control.  The F+LVAD group had Kds of 
289.40 ± 30.92 pM, resulting in a statistically significant increase in Kd versus control. 
 
3.2  Percents of Muscarinic Receptor Subtypes in NF, F, and F+LVAD Tissue 
 Muscarinic receptor subtypes were measured in NF, F, and F+LVAD left ventricular 
tissue.  Thirty-six of the samples used to measure total muscarinic receptor densities were 
also used to measure percents of muscarinic receptor subtypes using the time-dependent 
competition binding assay (tissue from patients highlighted in grey on Table I).  Once all 
data was collected, the percent of each subtype was compared.  The raw data results for 
each subtype are depicted in Figures 17-20.  The percent of M1 subtype, as shown in 
Figure 17, was 15.63 ± 3.11 in NF tissue, 12,96 ± 3.15 in F, and 21.28 ± 1.96 in 
F+LVAD.  Although the percent of M1 appears to be lower in failure and increase back 
up upon LVAD support, the differences did not reach statistical significance.  The 
percent of muscarinic receptor subtype M2 also did not change from NF to F or 
F+LVAD.  With percents of 61.60 ± 2.93 (NF), 60.19 ± 1.82 (F), and 62.86 ± 2.25 
(F+LVAD), depicted in Figure 18, the percent of M2s stayed the same in each group.  
Figure 19 shows the results of M3.  The percent of M3 was 19.83 ± 3.73 in NF, 10.97 ±  
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Figure 17.  Percents of M1 Receptor Subtype (Raw Data).  
Before normalizing to 100%, a 1-way ANOVA detected no 
significant changes in the percents of M1 found in each group 
(p=0.127). 
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Figure 18.  Percents of M2 Receptor Subtype (Raw Data).  
Before normalizing to 100%, a 1-way ANOVA detected no 
significant changes in the percents of M2 found in each group 
(p=0.730). 
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Figure 19.  Percents of M3 Receptor Subtype (Raw Data).  
Before normalizing to 100%, a 1-way ANOVA detected a 
significant decrease in the percent of M3 receptor subtype in F 
tissue compared to control (* p<0.05).  A significant increase 
was found in the F+LVAD group versus the F group (§§ 
p<0.01). 
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Figure 20.  Percents of M4 Receptor Subtype (Raw Data).  
Before normalizing to 100%, a 1-way ANOVA was performed 
and detected no significant changes in the percents of M4 found 
in each group (p=0.495). 
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2.52 in F, and 24.89 ± 2.09 in F+LVAD.  The percent of M3 did significantly decrease 
from NF to F (p<0.05) and increase back up from F to F+LVAD (p<0.01).  The percents 
of M4 did not significantly change between the three groups.  As shown in Figure 20, the 
percents of M4 were 33.97 ± 2.93 in NF, 31.53 ± 2.75 in F, and 36.21 ± 2.60 in F+LVAD.   
 On a heart to heart analysis, the percents of M1, M2, M3, and M4 equated to a value not 
equal to 100%.  This was not a surprising find due to the four subtype selective 
antagonists not being absolutely subtype selective.  Because of this, it was also important 
to normalize each heart to 100% and compare the results to the raw data.  Figure 21 
shows the percents of M1 once data was normalized to 100%.  With percents of 12.03 ± 
1.33 in NF, 9.97 ± 1.95 in F, and 14.47 ± 1.11 in F+LVAD, no statistically significant 
differences were found between groups.  Looking at the raw percents of M1 in Figure 17 
and the normalized graph in Figure 21, both sets of data show a slight loss in failure and 
increase back upon LVAD support.  Figure 22, the normalized percents of M2, show 
49.29 ± 2.75 in NF, 53.34 ± 3.29 in F, and 43.75 ± 1.20 in F+LVAD.  Like the raw data 
in Figure 18, no significant differences were found when comparing NF and F groups.  A 
difference only detected in the normalized data was the decrease in percent M2 upon 
LVAD support compared to the percent in failure (p<0.05).  The percent of M3s once 
normalize, in Figure 23, revealed the same results as the raw data.  There was a 
significant decrease in the percent M3 in F (8.61 ± 1.65) versus NF (13.56 ± 2.16) with 
recovery from failure upon LVAD support (16.65 ± 0.72).  The percents of M4s 
normalized also showed the same results as the raw results.  Figure 24 shows the results 
with 25.19 ± 0.93 in NF, 26.41 ± 0.67 in F, and 25.83 ± 1.37 in F+LVAD.   
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Figure 21.  Percents of M1 Receptor Subtype (Normalized Data).  
After normalizing to 100%, a 1-way ANOVA was performed and 
detected no significant changes in the percents of M1 found in 
each group (p=0.124). 
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Figure 22.  Percents of M2 Receptor Subtype (Normalized Data).  
After normalizing to 100%, a 1-way ANOVA was performed and 
detected no significant changes in the percents of M2 from F to NF 
tissue.  A significant decrease in the percent M2 receptor subtype was 
found in the F+LVAD group versus the F group (§ p<0.05). 
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Figure 23.  Percents of M3 Receptor Subtype (Normalized Data).  
After normalizing to 100%, a 1-way ANOVA detected a significant 
decrease in the percent of receptor subtype M3 in the F group versus 
control (* p<0.05) and a significant increase in the percent of 
receptor subtype M3 in the F+LVAD group versus the F group 
(§§ p<0.01). 
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Figure 24.  Percents of M4 Receptor Subtype (Normalized Data).  
After normalizing to 100%, a 1-way ANOVA was performed and 
detected no significant changes in the percents of M4 found in each 
group (p=0.714). 
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 It was difficult to make conclusions about each receptor subtype in failure and with 
mechanical unloading for several reasons.  First, the technique used only produced the  
percent of each subtype in LV samples, not the density.  While making conclusions about 
the percent of each subtype is sufficient, the potential change in subtype density may not 
mirror the same differences.  Also, the lack of absolutely subtype selective antagonists 
for these subtypes made it more difficult to interpret the data.  Because M1 and M3 
subtypes couple to the same G protein and stimulate the same signaling pathway, the 
percent of these two subtypes together were also determined for each group.  Figure 25 
shows these results.  It was found that the percent of M1 + M3 was 26.82 + 2.28 in NF, 
20.25 ± 2.94 in F, and 31.11 ± 1.35 in F+LVAD.  The percent of these odd-numbered 
subtypes did not significantly change in failure versus control.  Upon LVAD support, the 
percent of M1 + M3 significantly increased versus failure.  M2 and M4 couple to the same 
G protein and stimulate the same signaling pathway, therefore the percent of these 
subtypes together were also determined for each group.  as shown in Figure 26, the 
percent of M2 + M4 were 73.24 ± 2.31 in NF, 79.75 ± 2.94 in F, and 68.89 ± 1.35 in 
F+LVAD.  No significant differences were found between NF and F groups.  Upon 
LVAD support, there was a significant decrease in the percent of M2 + M4 versus the 
percent in failure.    
 
3.3  Muscle Function Analysis 
 Table II shows the patient population used to study muscle function on fresh cardiac 
muscles of the left ventricle.  Twenty patients were used, including 11 representing NF  
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Figure 25.  Percents of M1 and M3 Receptor Subtypes.  M1 and 
M3 receptor subtypes couple to Gq proteins to elicit the same 
downstream signaling pathway.  Percents of these odd-
numbered subtypes were added together on a heart-by-heart 
basis and a 1-way ANOVA found no significant change in these 
receptor subtypes in F tissue versus NF tissue, but a significant 
increase in F+LVAD versus F tissue (§§ p<0.01).     
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Figure 26.  Percents of M2 and M4 Receptor Subtypes.  M2 and 
M4 receptor subtypes couple to Gi proteins to elicit the same 
downstream signaling pathway.  Percents of these even-
numbered subtypes were added together on a heart-by-heart 
basis, and a 1-way ANOVA found no significant change in 
these receptor subtypes in F tissue versus NF tissue, but a 
significant decrease in F+LVAD versus F tissue (§§ p<0.01). 
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Table II.  Characteristics of Patients Used in Muscle Function Studies.  
Left ventricular (LV) tissue samples were taken from 20 patients, 11 
representing NF tissue and 9 representing F tissue.  Ages ranged from 39-
74 years with both males (M) and females (F) included in the experiment.  
Ejection fractions needed to be ≥50% in the NF tissue and ≤35% in the F 
group.  Common medications taken by each patient are listed above.  
(Abbreviations:  MET = Metoprolol, CAP = Captopril, AM = Amiodarone, 
LIS = Lisinopril, DIG = Digoxin, EPI = Epinephrine, MIL = Milrinone, 
CARV = Carvedilol, NE = Norepinephrine)   
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tissue and 9 HF patients.  The ages of patients studied ranged from 39-74 years old with
both males and females included in the study.  Ejection fractio
 
ns were greater than 50% 
h 
.  
e 
trol and drug-treated muscles was due 
or each 
no significant differences were found when comparing NF time control to NF 
Ch-treated, F time control to F ACh-treated, or NF ACh-treated to F ACh-treated.   
in all NF tissue and less than 35% in HF patients.  Common medications used by eac
patient included β-blockers, ACE inhibitors, and inotropes.   
 Before adding acetylcholine (ACh) or isoproterenol (ISO) to the muscles, the six 
contractile parameters were recorded for both time control and drug-treated muscles
Table III and Table IV represent the baseline results.  When comparing all NF muscles 
(time control and ACh-treated) to F muscles (time control and ACh-treated), initial 
differences were found in developed tension, time to peak tension, and time to half 
relaxation.  This is not surprising because failing tissue has been found to have less 
contractile abilities than non-diseased cardiac tissue.  Table IV compares the baselin
contractile parameters of time control versus ACh-treated muscles in each group.  No 
differences were found for any of the six contractile parameters.  This baseline data 
ensures that differences found between time con
strictly to the doses of ACh or ISO and not by differences in quality of the muscle.   
Dose-Response Curves Upon Additions of ACh 
 The contractile parameters were recorded after addition of each ACh dose.  F
parameter, comparisons were made between time control and ACh muscles in each 
sample group and comparing the addition of ACh between NF and F groups.   
 Figure 27 shows the resting tenstion (RT) results with addition of ACh.  At all six 
doses, 
A
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 Table III.  Baseline Contractile Parameters in NF and F Muscles.  
Baseline contractile parameters were compared in NF and F tissue 
groups.  no significant changes in RT, +dT/dt, or –dT/dt were 
detected from F to NF groups.  Significant decreases were found in 
DT (p<0.05), TPT (p<0.001), and THR (p<0.001) in failure versus 
non-diseased tissue. 
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 Table IV.  Baseline Contractile Parameters in Muscles to be 
Treated with ACh and Those Muscles Serving as Time 
Control (TC).  NF and F tissue was divided into muscles that 
would be treated with doses of ACh and those to serve as a 
control.  Before the experiment, contractile parameters were 
compared between the ACh-treated muscles and TC muscles in 
both tissue types.  No significant differences were found in 
either tissue group. 
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Figure 27.  Dose-Response to ACh – Resting Tension (RT) Results.  
No significant changes were found between NF muscles treated with 
ACh and those serving as time control (TC) [top graph].  No significant 
changes were found between F muscles treated with ACh and those 
serving as TC [middle graph].  No significant differences were detected 
in the percent change of RT in ACh-treated F muscles verses ACh-
treated NF muscles [bottom graph]. 
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 Figure 28.  Dose-Response to ACh – Developed Tension (DT) Results.  No 
significant changes were found between NF muscles treated with ACh at lower 
doses and those serving as time control (TC), however addition of the two 
highest doses of ACh resulted in a significant recovery in the percent change of 
DT compared to control [top graph] (p<0.001).  No significant changes were 
found between F muscles treated with ACh at lower doses and those serving as 
TC, however addition of the two highest doses of ACh resulted in a significant 
recovery in the percent change of DT compared to control [middle graph] 
(**p<0.01; ***p<0.001).  No significant differences were detected in the percent 
change of DT in ACh-treated F muscles verses ACh-treated NF muscles [bottom 
graph]. 
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 The results for developed tension (DT) are depicted in Figure 28.  NF muscles treated 
with ACh at lower doses (1, 10, and 100 nM and 1 µM) produced no change in DT  
compared to time control.  When 10 µM and 100 µM of ACh were added, treated 
muscles significantly recovered their percent change in DT compared to time control (10 
µM:  -10.50 vs -23.10 (p<0.001);  100 µM:  -6.90 vs -25.35 (p<0.001)).  The middle 
graph shows the same comparison, but with the F tissue group.  Again, the two highest 
doses of ACh showed a significant recovery in DT compared to the time control muscles 
(10 µM:  -4.96 vs -15.44 (p<0.01);  100 µM:  -3.12 vs -19.45 (p<0.001)), while the four 
lower doses of ACh produced no change in response compared to control.  The response 
of ACh addition was compared between the two groups of tissue as well.  ACh doses 
elicited the same effect at all six doses in both NF and F muscles, with no significant 
changes in their DT found.   
 Time to peak tension (TPT) was the next parameter compared.  In Figure 29, no 
significant differences were found between time control and ACh-treated muscles in NF 
tissue and F tissue.  Figure 29 also shows the comparison of ACh addition in NF tissue 
versus ACh addition in F tissue.  While the NF muscles continue to decrease from 
baseline upon each dose addition, F muscles preserve their TPT, with values closely 
mimicking baseline values at all six doses.  Here, 1, 10, or 100 nM of ACh did not 
significant change the TPT between F and NF muscles.  At 1 µM, F muscles had a 
percent change in TPT of -0.40 and NF muscles -3.94; a statistically significant change 
found (p<0.05).  Differences were also detected at 10 µM and 100 µM ACh-treatments 
(10 µM:  -0.08 (F) vs -3.39 (NF) (p<0.05);  100 µM:  0.13 (F) vs -3.90 (NF) (p<0.01)). 
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Figure 29.  Dose-Response to ACh – Time to Peak Tension (TPT) Results.  
No significant changes were found between NF muscles treated with ACh and 
those serving as time control (TC) [top graph].  No significant changes were 
found between F muscles treated with ACh and those serving as TC [middle 
graph].  Significant differences were detected in the three highest doses of 
ACh in F tissue versus NF tissue [bottom graph] (*p<0.05; **p<0.01). 
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Figure 30.  Dose-Response to ACh – Time to Half Relaxation (THR) Results.  
No significant changes were found between NF muscles treated with ACh and 
those serving as time control (TC) [top graph].  No significant changes were found 
between F muscles treated with ACh and those serving as TC [middle graph].  No 
significant differences were detected in the percent change of THR in ACh-treated 
F muscles verses ACh-treated NF muscles [bottom graph]. 
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Figure 31.   Dose-Response to ACh – Peak Rate of Tension Rise (+dT/dt) Results.  
Significant differences were found between NF muscles treated with the two highest 
doses of ACh and those serving as time control (TC) [top graph] (*p<0.05; 
**p<0.01).  No significant changes were found between F muscles treated with ACh 
and those serving as TC [middle graph].  No significant differences were detected in 
the percent change of +dT/dt in ACh-treated F muscles verses ACh-treated NF 
 
 
muscles [bottom graph].  
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 Figure 30 shows the time to half relaxation (THR) results.  No significant changes 
were detected between time control and ACh muscles of NF tissue or time control and 
 
e  
 -
F 
 
d similarly to the NF tissue, however no significant changes were detected.  
F 
se 
ontrol  in 
respect to –dT/dt. 
ACh muscles of F tissue (shown in Figure 30a and 30b).  NF and F tissue, with addition
of ACh, did not produce any significant changes at any of the six doses either.   
 The results of peak rate of tension rise (+dT/dt) were compared in Figure 31.  In NF 
tissue, the time control muscles continually decreased in percent with time, while thos
treated with ACh recovered toward baseline +dT/dt values as the concentration of ACh 
increased.  With the addition of 10 µM ACh, ACh-treated NF muscles had a percent 
change +dT/dt of -2.96 while time control NF muscles had a percent change +dT/dt of
16.41, a significant change in response (p<0.05).  Upon addition of 100 µM ACh, N
muscles had a percent change +dT/dt of -0.40 versus the time control NF muscles of -
16.27 (p<0.01).  This resulted in a significant increase of +dT/dt with the two most 
concentrated doses of ACh versus control.  The F tissue, depicted in Figure 31(middle
graph), trende
In comparing the addition of ACh between NF and F tissue, no significant differences 
were found.   
 –dT/dt, shown in Figure 32, show the same changes as +dT/dt.  When comparing N
time control to NF ACh, the two highest doses of ACh resulted in a significant increa
in     -d
100 µM
T/dt versus control (10 µM:  -4.24 (ACh-treated) vs -18.13 (control) (p<0.01);  
:     -1.32 (ACh-treated) vs -19.26 (control) (p<0.001).  In comparing F time 
 to F ACh and ACh addition in NF and F tissue, no significant changes occurredc
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 Figure 32.  Dose-Response to ACh – Peak Rate of Tension Fall (-dT/dt) Results.  
Significant differences were found between NF muscles treated with the two 
highest doses of ACh and those serving as time control (TC) [top graph] (*p<0.05; 
**p<0.01).  No significant changes were found between F muscles treated with 
ACh and those serving as TC [middle graph].  No significant differences were 
detected in the percent change of -dT/dt in ACh-treated F muscles verses ACh-
treated NF muscles [bottom graph]. 
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Addition of Isoproterenol (ISO) 
 One dose of the β-AR agonist ISO was added to both time control and ACh-treated 
muscles after the ACh dose-response experiments were completed.  Results are expressed 
s 
ling 
 
ase in 
9%.  
ing).  
ooking at non-failing tissue only, there was a significant difference in the percent  
as the mean percent change from a time immediately before addition of ISO. 
 The RT results upon addition of ISO are depicted in Figure 33.  Time control and 
ACh-treated muscles had significantly different RTs from failing to non-failing group
(TC: -3.9 vs -11.52, p<0.001;  ACh: -3.9 vs -9.3, p<0.01).  Non-failing muscles had 
comparable RTs in ACh-treated muscles compared to control (-9.3 vs -11.5) and fai
muscles had comparable RTs in ACh-treated versus control groups (-3.9 vs -3.9).   
 Figure 34 represents DT data collected upon addition of ISO.  Time control muscles 
had a significantly lower percent change in DT in failing versus non-failing tissue (127.5 
vs 191.6, p<0.01).  ACh-treated muscles also had a significantly lower percent change in
DT in failing versus non-failing tissue (47.9 vs 109.8, p<0.001).  Looking at the change 
in non-failing tissue, there was ~43% decrease in DT in ACh-treated muscles compared 
to control (109.8-191.6 / 191.6 = 42.7%).  In failing tissue, there was ~62% decre
DT in ACh-treated muscles compared to control (47.9-127.5 / 127.5 = 62.4%).  
Therefore, failing tissue had a greater negative response to DT by approximately 1
 TPT, depicted in Figure 35, significantly changes between sample groups and 
between drug treatment.  There was a significantly greater change in TPT in non-failing 
muscles than failing muscles for both time control and ACh-treated groups (time control: 
-36.9 in non-failing; -18.3 in failing) (ACh-treated: -28.0 in non-failing; -12.4 in fail
L
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 Figure 33.  Resting Tension (RT) – Isoproterenol (ISO) Response.  
Both time control (TC) and ACh-treated muscles had a significantly 
less percent change in F tissue versus NF tissue after addition of 
ISO (** p<0.01; *** p<0.001).  Addition of ACh had no significant 
change in the effect of ISO in NF or F groups. 
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 Figure 34.  Developed Tension (DT) – Isoproterenol (ISO) Response.  
Both time control (TC) and ACh-treated muscles had a significantly 
less percent change in F tissue versus NF tissue after addition of ISO 
(** p<0.01; *** p<0.001).  Addition of ACh significantly decreased the 
percent change in DT in NF tissue (43% decrease) and F tissue (62% 
decrease) compared to muscles only treated with ISO (§§§ p<0.001).   
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 Figure 35.  Time to Peak Tension (TPT) – Isoproterenol (ISO) Response.  
Both time control (TC) and ACh-treated muscles had a significantly less 
percent change in F tissue versus NF tissue after addition of ISO 
(***p<0.001).  Addition of ACh significantly decreased the percent change 
in TPT in NF tissue and F tissue compared to muscles only treated with ISO 
(§§§ p<0.001; §§ p<0.01).   
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 Figure 36.  Time to Half Relaxation (THR) – Isoproterenol (ISO) Response.  
Time control (TC) and ACh-treated muscles had no significant percent change in 
F tissue versus NF tissue after addition of ISO.  Addition of ACh significantly 
decreased the percent change in THR in F tissue compared to muscles only 
treated only with ISO (§§ p<0.01).  Addition of ACh did not significantly change 
in THR in NF tissue versus TC. 
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change of TPT from ACh-treated muscles versus time control (-28.0 vs -36.9).  Also, the 
percent change in TPT was significantly different in failing versus non-failing tissue (-
12.4 vs -18.3). 
 The next contractile parameter analyzed was THR.  As shown in Figure 36, THR in 
time control muscles did not significantly change in failing tissue versus control (-26.7 vs 
-23.3).  ACh-treated muscles also did not significantly change in failing versus non-
failing muscles (-16.2 vs -18.1).  THR was comparable in non-failing and ACh-treated 
muscles (-23.3 and –18.1) while THR in failing muscles was significantly different in 
ACh-treated versus time control muscles (-16.2 vs -26.7). 
 +dT/dt, in Figure 37, did not significantly change when comparing ACh-treated 
muscles in failing versus non-failing groups (37.5 vs 116.7).  There was a significant 
percent change in +dT/dt in time control muscles comparing failing to non-failing tissue 
(112.0 vs 253.7, p<0.001).  Both non-failing and failing muscles did significantly change 
in +dT/dt when comparing ACh-treated to time control muscles (non-failing: 116.7 v 
253.7, p<0.001;  failing:  37.5 vs 112.0, p<0.05). 
 -dT/dt, shown in Figure 38, did not significantly change when comparing ACh-treated 
muscles in failing versus non-failing groups (37.2 v 94.6).  There was a significant 
percent change in –dT/dt in time control muscles comparing failing and non-failing tissue 
(114.2 vs 215.3, p<0.01).  Both non-failing and failing muscles did significantly change 
in –dT/dt when comparing ACh-treated to time control muscles (non-failing:  94.6 vs 
215.3, p<0.001;  failing:  37.2 vs 114.2, p<0.05). 
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 Figure 37.  Peak Rate of Tension Rise (+dT/dt) – Isoproterenol (ISO) Response.  
Time control (TC) muscles had significantly less of a response in F tissue versus NF 
tissue to ISO (*** p<0.001).  Addition of ACh significantly decreased the +dT/dt in 
F and NF muscles versus their respective TC group (§§§ p<0.001; § p<0.05). 
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 Figure 38.  Peak Rate of Tension Fall (-dT/dt) – Isoproterenol (ISO) Response.  
Time control (TC) muscles had significantly less of a response in F tissue versus 
NF tissue to ISO (** p<0.01).  Addition of ACh significantly decreased the -dT/dt 
in F and NF muscles versus their respective TC group (§§§ p<0.001; § p<0.05). 
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CHAPTER IV 
DISCUSSION 
 
 
4.1  Effect of Total Muscarinic Receptor Density and Affinity in Failure and Upon 
LVAD Support 
 ANS imbalance is a characteristic in HF.  The SNS has been the focus of research for 
the past 20+ years, resulting in definitive conclusions about its role in failure.  With the 
consensus that the SNS is overactivated in HF, leading to a significant downregulation of 
β-ARs, new drug therapies targeting β-ARs were introduced.  Research on the PNS in HF 
has led to conflicting results, allowing for no consensus to be reached and potential 
therapies targeting the PNS disregarded.  Muscarinic receptor densities have been studied 
in various models of HF, however inconsistent findings have led to more confusion and 
less conclusions about the PNS in HF. 
 Some early studies of muscarinic receptors report a significant decrease in receptor 
density in failure.  Vatner et al in 1988 used left ventricular sarcolemma from mongrel 
canines to measure muscarinic receptor densities.  With control (n=10) and HF (n=8) 
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they found densities to be significantly reduced (3.6 ± 0.4 versus 5.6 ± 0.6 pmol/mg, 
p<0.05) in the canine model of HF56.  Mertens et al used rat left ventricular tissue (n=6 
per group) to determine a significant decrease in muscarinic receptor density compared to 
control (221.0 ± 8.9 versus 308.8 ± 16.1 fmol/mg, p<0.05)37. 
 The first human studies on muscarinic receptor densities found no significant changes 
between non-failing and failing tissue.  Bohm and colleagues used 16 patients with DCM 
and coronary artery disease (CAD), aged between 21-59 years, against 5 controls (22-31 
years old).  They found no significant change in receptor density (275 ± 21 versus 211 ± 
22 fmol/mg in failure)3.  A review in 1999 by Giessler and others highlighted the work 
done on muscarinic receptors up to that time.  Their own research examined muscarinic 
receptor density in right atrium and left ventricle tissue.  The densities did go up in HF 
(n=11) compared to control (n=5) but not enough to be statistically significant.  It is 
important to point out that in this case, 5 control hearts came from patients with a mean 
age of 33 years old while the 11 HF patients had a mean age of 51 years old19.   
 Coinciding with our current findings, researchers in France used positron emission 
tomography (PET) to find a significant upregulation of muscarinic receptor density in HF 
patients (n=20) compared to control (n=12) (p<0.005)32.  Wilkinson and colleagues 
examined atrial and ventricular muscarinic receptor densities in a canine model of HF.  
No significant differences in density were found in the atrium but a significant increase in 
muscarinic receptor density was found in the left ventricular HF model.  Using n=4 (HF) 
versus n=6 (control), they found densities to be 245.0 ± 25.0 fmol/mg protein in failure 
compared to 160.0 ± 10.0 fmol/mg in control (p<0.01)60.  Vatner et al also found a 
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significant increase in muscarinic receptors in the pacing model of HF.  Canines with HF 
were found to have densities 153.0 ± 6.2 fmol/mg versus 124.0 ± 7.4 fmol/mg in control.  
Vatner et al had previously found a significant decrease in muscarinic receptor density in 
a canine model of HF (induced by aortic banding) and stated that differences found 
between these experiments were due to differing models of HF57. 
 This current study was aimed to clarify the conflicting results generated by the past 
twenty years of research on muscarinic receptors in relation to HF.  Several differences 
from previous studies to this current study include the model being tested, age, and 
sample size.  Model differences may factor in differing results because muscarinic 
receptor densities may be different among species.  Also, animal models do not form HF 
over a prolonged, natural time course.  The difference in disease acquisition may add to 
conflicting muscarinic receptor density findings.  Age is also an important factor in 
choosing a sample population, especially when measuring muscarinic receptors.  It is 
established that muscarinic receptor density is significantly decreased as age increases, 
therefore, studies with large differences in age may not appropriately respresent 
muscarinic receptor density6.  Finally, sample sizes may contribute to differing 
conclusions.  With a small sample size, such as five, differences in density are more 
difficult to detect. 
 With a large sample selection of human hearts from patients with a similar mean age, 
this study found total muscarinic receptor density to be significantly upregulated in the 
failing heart (275.8 ± 11.9 vs 194.1 ± 17.3 fmol/mg (p<0.01)) and even more 
significantly upregulated upon LVAD support compared to control (315.8 ± 11.9, 
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p<0.001).  A significant increase in receptor density may be opposing β-AR stimulation 
by inhibiting the adenylyl cyclase, cAMP pathway that is overactivated in the failing 
human heart.  Because M2 receptors are predominant, and they act by inhibiting this 
pathway, an increase in density may be a mechanism for reducing sympathetic 
overstimulation.  Upons LVAD support, muscarinic receptors remain upregulated 
compared to control.  β-AR densities recover with LVAD support, having densities after 
an LVAD mimicking non-failing values, therefore, our findings on tissue with LVAD 
support are surprising42.  Although the reason why muscarinic receptor densities remain 
upregulated in LVAD remains unknown, one could speculate that it is in response to an 
increase in β-AR density. 
 An upregulation of muscarinic receptor density in failure is clear, and is further 
supported by previous studies that found Gi protein, that which couples M2/4 receptors, 
also upregulated in failure2,17,57.  This increase in Gi provides evidence that the effects 
regulated by M2/M4 receptors are increased in HF2.  M2/4 receptors inhibit AC, cAMP 
pathway using Gi only when the pathway is turned on by the SNS.  During failure, the 
PNS may act to increase opposition of established SNS overstimulation by increasing the 
amount of muscarinic receptors.  More muscarinic receptors coupled to Gi would be able 
to inhibit the overactivated SNS. 
 PNS activity on the heart is regulated at various levels, therefore muscarinic receptor 
density and Gi protein levels alone cannot be the answer to PNS control on the heart.  
Although muscarinic receptors act as the target of the PNS on cariomyocytes, the vagus 
nerve is an important regulator of the PNS and is found to have diminished control in 
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HF61.  Recent studies have found vagal nerve stimulation to increase survival and 
improve autonomic balance in animal models of HF61.  No current study has performed 
vagal nerve stimulation and then measured muscarinic receptor density on 
cardiomyocytes, although it would be interesting to see if stimulation of the vagus nerve 
produces changes on receptor density. 
 When looking at antagonist affinity to muscarinic receptors, this current study found 
no significant change in affinity between NF and F groups.  However, a significant loss 
in affinity was found in F+LVAD versus control.  Our findings in NF and F human hearts 
were in agreement to other studies that found no change in affinity between 
groups3,32,56,57.  To our knowledge, this is the first study to measure muscarinic receptors 
upon LVAD support, therefore the only study to find changes in affinity.  LVADs have 
been shown to recover remodeling in the failing heart, including restoring β-AR density 
to NF values.  A possible reason the antagonist affinity decreases upon LVAD support 
may be because a significant increase in receptor stimulation is no longer necessary.  
Receptors may conformationally change or desensitize in response to SNS regulation.      
 
4.2  Muscarinic Subtypes in the Non-failing, Failing, and LVAD Human Hearts 
 The functional role of muscarinic receptor subtypes was not realized until the 1990s58.  
In the heart, M2 was accepted as the only functional subtype until studies on rats, chicks, 
canines, and other species found non-M2 subtypes existing52,58.  The first human study to 
detect multiple muscarinic receptor subtypes in the heart was published in 200158.   
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 In this current study, we were able to support the idea that there are multiple 
muscarinic receptor subtypes in the NF, F, and F + LVAD support human heart.  Using 
non-labeled subtype selective antagonists at established Ki concentrations, we were able 
to fraction subtypes in our three sample populations.  Because each heart resulted in a 
percent binding over 100%, we chose to interpret the raw data and to normalize the data 
to 100%. 
 When looking at the raw data, we found no significant change in the percent of M1, 
M2, or M4 between NF, F, and F+LVAD.  The percent of M3 significantly decreased in 
failure compared to control and significantly increased back up to NF results upon LVAD 
support.  When looking at the normalized data, we found no significant change in the 
percent of M1 or M4 between NF, F, and F+LVAD groups.  The same change in the 
percent of M3 was found once normalized, significantly decreasing in failure compared to 
control and significantly increasing back to NF results upon LVAD support.  The one 
difference between the normalized and raw data was with the percent of M2.  When 
comparing NF to F groups, the percents did not significantly change in either 
representation of the data.  However, once normalized there was found to be a significant 
decrease in the percent of M2 upon LVAD support compared to control, a difference not 
detected in the raw data. 
 The percents of M1, M2, and M4 did not change significantly between the groups 
tested, although a change in receptor density should not be disregarded.  We do not know 
how the densities of each subtype change in response to failure or LVAD support, 
however with data we have found, we can speculate about how the subtypes may change 
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in density.  For example, we know total muscarinic receptor density is upregulated both 
in F and F+LVAD support compared to NF tissue.  We may speculate that the 
predominant subtypes, M2 and M4, which are also the receptors coupled to the inhibitory 
Gi protein, increase in density while the density of M1 and M3 stay the same, 
respectively.  This speculation could result in the percent of M2 and M4 staying the same, 
with a slight decrease in the percent of M1 and M3 (significant enough for M3 because the 
percent in the left ventricle is only a small fraction of the whole).  This is one possible 
mechanism to explain total density increasing with percents changing as described above, 
although other mechanisms are also possible.      
 Our study was the first to measure the percent of muscarinic subtypes in NF, F, and 
F+LVAD tissue; however researchers have examined the idea of multiple subtypes 
existing in the non-diseased human heart.  Huizen Wang and colleagues used multiple 
experimental techniques to detect muscarinic receptor subtypes.  They performed 
competition binding studies using pirenzepine, methoctramine, 4-DAMP, and 
tropicamide to detect the percent binding of antagonists to receptor subtypes.  Their data 
found (in %) 30.3 ± 10.4 using pirenzepine, 78.2 ± 9.8 with methoctramine, 15.4 ± 2.5 
for 4-DAMP, and 18.7 ± 8.4 using tropicamide.  Unlike our current study, Want et al 
performed competition binding studies with varying doses of each non-labeled subtype 
selective antagonist, while we kept the antagonist concentration constant and varied the 
time of incubation.  By varying the concentration of selective antagonists, they were able 
to yield pKi values.  Using previous literature and established pKi values for each 
subtype binding to antagonists, these researchers concluded that pirenzepine was binding 
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to M1 receptors, methoctramine to M2, 4-DAMP to both M3 and M1, and tropicamide to 
M3 and M2.  Therefore, they detected the presence of M1, M2, and M3 receptors using 
competition binding experiments.  They also used reverse-transcriptase polymerase chain 
reaction (RT-PCR), Western blotting, and confocal microscopy to examine the 
muscarinic receptor subtypes.  Results from Western blotting and confocal microscopy 
supported the presence of M1, M2, M3, and M5 subtypes.  Neither technique was able to 
detect M4.  RT-PCR, on the other hand, detected the presence of mRNA for all five 
subtypes58. 
 More recently, Perez and others examined the existence of non-M2 subtypes in the 
human heart using immunoblotting, ELISA, and RT-PCR.  All three experimental 
techniques supported the idea that all 5 muscarinic receptor subtypes are present in 
human atrial and ventricular tissue.  They further suggest that these subtypes are able to 
act as non-interacting monomers and interacting oligomers46. 
 With multiple subtypes existing in the human heart, multiple signaling pathways and 
elicited responses must be present.  In the ventricles, M2 and M4 subtypes couple to the 
inhibitory Gi protein.  Upon activation, Gi inhibits adenylyl cyclase which decreases 
levels of cAMP and PKA activity.  This effects Ca++-cycling proteins on the SR, 
producing a negative chronotropic and inotropic effect on the heart.  M1, M3, and M5 
activate stimulatory pathways and are coupled to Gq proteins.  Upon activation, PLC is 
stimulated which cleaves phosphatidylinositol bisphosphate (PIP2) into IP3 and DAG.  
Recently, Kitazawa et al used mice atria to demonstrate a positive inotropic response 
upon activation of M3.   
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4.3  Muscle Function 
 Muscle function experiments were performed to see if a relationship existed between 
total muscarinic receptor density differences in non-failing and failing hearts and the 
functional response of cardiac muscle.  We speculated that, because a significant increase 
in muscarinic receptor density exists in failing tissue, the negative inotropic and 
chronotropic effects on the heart would be greater in failure. 
 Baseline parameters were measured to ensure that differences found in the six 
contractile parameters were due to drug responses and not to initial differences in muscle 
function.  As shown in Table III, failing tissue was found to have significantly decreased 
developed tension (DT), time to peak tension (TPT), and time to half relaxation (THR) 
than the non-failing groups.  This phenomenon has been shown in previous work, 
indicating that failing tissue is weaker than healthy, non-diseased hearts.  Because of 
differences in the contractile function of tissue groups, data was represented as a percent 
change from baseline.  Muscles within each group were also analyzed at baseline.  Table 
IV shows that time control and ACh-treated muscles began at comparable contractile 
measurements in both non-failing and failing groups.   
 Looking at the resting tension (RT) contractile parameter upon addition of ACh doses, 
this parameter does not significantly change between non-failing and failing muscles 
treated with ACh, or when comparing non-failing time control and ACh muscles, and 
failing time control and ACh-treated muscles (shown in Figure 24).  RT is the amount of 
tension generated while the muscle is not contracting.  Because RT does not require 
stimulation of contraction or is in response to muscarinic stimulation, this lack of changes 
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found is not surprising.  These results do demonstrate the loss in RT, with or without 
ACh-treatement – as a result of time. 
 Developed tension (DT) is one of the most important of the six contractile parameters 
measured because it is the tension produced from a muscle’s resting state to the highest 
point of contraction.  DT is a direct measure of muscle function and how well the muscle 
is contracting.  As shown in Figure 25, lower doses of ACh produce no change in DT 
compared to control.  However, when higher doses of ACh were added, DT recovered 
compared to control in both non-failing and failing tissue.  Because this dose-response 
curve was in the absence of β-AR stimulation, higher doses of ACh could be stimulating 
the less predominant muscarinic receptor pathway (M1/M3/M5).  If this were true, these 
muscarinic receptors would stimulate Ca++ movement within cells, causing a positive 
response to ACh.  It is important to note that, although the two highest doses of ACh 
elicit recovery in DT in both groups, their response is still negative compared to baseline 
measures.  If these higher doses were added initially, they may or may not have produced 
a positive response on DT.  Also, when looking at ACh-treated muscles in failing versus 
non-failing tissue, no statistically significant differences were found.  Therefore, ACh 
without stimulation of β-AR signaling did not change how well the muscle was 
contracting in failing hearts versus non-failing hearts.   
 One of the timing parameters, time to peak tension (TPT), did not shown significant 
differences when comparing time control and ACh-treated muscles in each group.  The 
percent change from baseline declined as time increased in both time control and ACh-
treated muscles in the healthy heart.  Failing tissue did not decline as great as non-failing 
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tissue, yet time control and ACh muscles produced the same effect.  When comparing 
ACh addition in failing to non-failing muscles, TPT significantly recovered to baseline in 
failing tissue while non-failing tissue continued to decline as ACh doses increased.  
Another timing parameter, time to half relaxation (THR), showed no changes between 
muscle types or between non-failing and failing ACh-treated muscles.  However, a high 
amount of variability may restrict differences from being found. 
 The peak rate of tension rise (+dT/dt) is the point where the muscle is contracting the 
fastest and the peak rate of tension fall (-dT/dt) is the point where the muscle is relaxing 
the fastest.  Neither of these parameters changed in time control or ACh-treated failing 
muscles nor did they differ when comparing failing ACh-treated muscles to non-failing 
ACh-treated muscles.  For both of these parameters, non-failing muscles treated with 
ACh at higher doses showed significant recovery compared to the non-failing time 
control muscles. 
 Adding ISO to all of the muscles at the end of the experiment allowed us to see the 
affect ACh had on muscles with sympathetic stimulation.  Most of the contractile 
parameters (all except for THR) elicited changes between failing and non-failing tissue, a 
response due to the difference in tissue type.  ACh-treated muscles also produced 
different responses compared to their time control counterparts in five of the six 
contractile parameters (all except for RT).    
 Landzberg and colleagues examined left ventricular contractility in six normal patients 
and seven patients 1-3 years after cardiac transplantation.  In this study, patients were 
infused with dobutamine, ACh, atropine, dobutamine + ACh, and dobutamine + atropine.  
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Left ventricular +dP/dt was measured five minutes after each infusion and after addition 
of a control (5% dextrose in water).  Results show that left ventricular +dP/dt 
significantly increases with addition of the β-AR agonist dobutamine.  ACh, the 
cholinergic agonist, alone did not produce a change in +dP/dt compared to control.  When 
ACh was infused with dobutamine, a small increase in +dP/dt was found.  This work 
shows that muscarinic stimulation or blockade modulates sympathetic activity, 
demonstrating the important interactions of the SNS and PNS to regulate functional 
responses of the heart30. 
 Another study, by Du et al, examined the effects of ACh and ACh with noradrenaline 
on human right atrial and left ventricular trabeculae from 61 donor hearts.  Similar to our 
findings, results from this experiment indicated that ACh elicited an increase in 
ventricular contractility at high doses.  However, when ACh was added after pre-
stimulation with noradrenaline, ACh decreased contractility.  They also showed that 
atropine blocked the positive inotropic response elicited by ACh alone and that these 
responses did not change when propranolol was introduced15.  
 
4.4  Summary 
 Total muscarinic receptor densities are upregulated in human HF.  This result could be 
in response to overactivated sympathetic stimulation.  Because the inhibitory muscarinic 
receptors, which take up approximately 80% of the total number of receptors, inhibit the 
β-AR stimulated pathway, an increase in muscarinic receptors may be a compensatory 
mechanism to antagonize the effects of the overstimulated SNS seen in HF.  This theory 
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is supported by previous studies that found a significant increase in Gi protein, that which 
couples M2 and M4, in human HF2.  In failing hearts with LVAD support, muscarinic 
receptor densities remain significantly upregulated versus control, instead of showing 
recovery to NF densities like β-ARs do upon LVAD support.  This may or may not be 
due to receptor subtype changes. 
 Muscarinic receptor subtypes differ in the G protein they couple, causing activation of 
different signaling pathways.  Even-numbered receptors couple Gi and produce a 
negative inotropic and chronotropic effect while odd-numbered receptors couple to Gq 
and produce a positive inotropic and chronotropic effect.  Because multiple muscarinic 
receptor subtypes exist that elicit opposite responses on the heart, the total density 
differences found between groups may be a result of one, a few, or all subtype densities 
changing.  With the differences found in the percent of each subtype in the various tissue, 
speculations may be made concerning the density differences of subtypes in each sample 
group.  Upon LVAD support, SNS balance has been found to be restored42.  With 
inhibitory receptor subtypes no longer needed in increased abundance, stimulatory 
receptors may be synthesized more to increase their fraction of total muscarinic receptors 
acting on cardiac myocytes. 
 The goal in investigating muscle function on NF and F tissue was to see if a 
relationship existed between the functional response of fresh cardiac muscles and the 
changes found in muscarinic receptor densities.  In the dose-response curves, a significant 
recovery was found when comparing higher doses of ACh to control muscles in both NF 
and F tissue types (DT, TPT, +dT/dt, and –dT/dt results).  With a lack of β-AR 
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stimulation, M2 and M4 receptor pathways may only be signaling constitutively.  M1, M3, 
and M5, with high concentrations of a ligand, elicit a positive response on contractility – 
resulting in the recovery seen in four of the contractile parameters.  Once ISO is added, 
M2 and M4 receptors are able to activate Gi and inhibit the AC-cAMP-PKA signaling 
pathway to produce an inhibitory response.  This is shown in DT, TPT, THR, +dT/dt, and 
–dT/dt contractile parameters. 
 Through the radioligand binding assays, competition binding assays, and muscle 
function analysis, it was shown that HF is associated with a significant increase in total 
muscarinic receptor density, which remains upregulated with LVAD support.  The 
percent of M1-M4 receptor subtypes differed in the patient populations as well, showing 
that muscarinic receptors play both an inhibitory and stimulatory role on heart rate and 
force of contraction.  The muscle function data supported the increase in total muscarinic 
receptor densities relating to greater decreases in muscle contractility measures.  In 
conclusion, it is known that the overactivated SNS is a target of therapy in human HF – 
which was found through years of research on its activity and signaling.  β-ARs are a 
target of medications that block the receptor from activating a stimulatory signaling 
pathway.  With findings from this current study and others, the role of the PNS may be 
further investigated as a target for novel therapeutic approaches in tackling human HF. 
 
 
 
 
 90
REFERENCES 
 
 
1. Bibevski, S. and Dunlap, M. E.  (2004).  Prevention of diminished 
parasympathetic control of the heart in experimental heart failure.  American 
Journal of Physiology.  287; H1780-H1785. 
 
2. Bohm, M., Gierschik, P., Jakobs, K.H., Pieske, B., Schnabel, P., Ungerer, M., and 
Erdmann, E.  (1990).  Increase of Gi alpha in human hearts with dilated but not 
ischemic cardiomyopathy.  Circulation.  82; 1249-1265. 
 
3. Bohm, M., Ungerer, M., and Erdmann, E.  (1990).  Beta adrenoceptors and m-
cholinoceptors in myocardium of hears with coronary artery disease or idiopathic 
dilated cardiomyopathy removed at cardiac transplantation.  American Journal of 
Cardiology.  66; 880-882. 
 
4. Bristow, M.R.  (2000).  Beta-adrenergic receptor blockade in chronic heart 
failure.  Circulation.  101; 558-569. 
 
5. Brodde, O.E, and Michel, M. C.  (1999).  Adrenergic and muscarinic receptors in 
the human heart.  Pharmacological Reviews.  651-675. 
 
6. Brodde, O.E., Konschak, U., Becker, K., Ruter, F., Poller, U., Jakubetz, J., Radke, 
J., and Zerkowski, H.R.  (1998).  Cardiac muscarinic receptors decrease with age.  
In vitro and in vivo studies.  Journal of Clinical Investigation.  2; 471-478. 
 
7. Cappola, T. P.  (2008).  Molecular remodeling in human heart failure.  Journal of 
the American College of Cardiology.  137-138. 
 
8. Caulfield, M. P.  (1993).  Muscarinic receptors:  Characterization, coupling and 
function.  Pharmacology and Therapeutics.  58; 319-379. 
 
9. Cohen-Armon, M., Schreiber, G., and Sokolovsky, M.  (1984).  Interaction of the 
antiarrhythmic drug amiodarone with the muscarinic receptor in rat heart and 
brain.  Journal of Cardiovascular Pharmacology.  6; 1148-1155. 
 
10. Colucci, W.S.  (1997).  Molecular and cellular mechanisms of myocardial failure.  
American Journal of Cardiology.  80; 15L-25L. 
 
11. Cox, E.A. and Kwatra, M.M.  (2007).  Inhibition of 3H-QNB binding to subtypes 
of muscarinic acetylcholine receptors by amiodarone.  Anesthesiology.  107; 
A1848. 
 
 91
12. Cullen, M.E., Yuen, A.H., Felkin, L.E., et al.  (2006).  Myocardial expression of 
the arginine:glycine amidinotransferase gene is elevated in heart failure and 
normalized after recovery: potential implications for local creatine synthesis.  
Circulation.  114; I16-20. 
 
13. DiPaola, N.R., Sweet, W.E., Stull, L.B., Francis, G.S., and Moravec, C.S.  (2001).  
Beta-adrenergic receptors and calcium cycling proteins in non-failing, 
hypertrophied, and failing human hearts:  transition from hypertrophy to failure.  
Journal of Molecular and Cellular Cardiology.  33; 1283-1295.   
 
14. Dipla, K, Mattiello, J.A., Jeevanandam, V., Houser, S.R., Margulies, K.B.  
(1998).  Myocyte recovery after mechanical circulatory support in humans with 
end-stage heart failure.  Circulation.  97; 2316-2322. 
 
15. Du, X.Y., Schoemaker, R.G., Bos, E., and Saxena, P.R.  (1995).  Characterization 
of the positive and negative inotropic effects of acetylcholine in the human 
myocardium.  European Journal of Pharmacology.  284; 119-127. 
 
16. Felder, C. C.  (1995).  Muscarinic acetylcholine receptors:  signal transduction 
through multiple effectors.  The FASEB Journal.  9; 619-625. 
 
17. Feldman, A., Cates, A., Bristow, M., Van Dop, C.  (1989).  Altered expression of 
the alpha-subunit of G proteins in failing human heart.  Journal of Molecular and 
Cellular Cardiology.  21; 359-365. 
 
18. Feldman, D. S., Carnes, C. A., Abraham, W. T., and Bristow, M. R.  (2005).  
Mechanisms of disease:  β-adrenergic receptors – alterations in signal 
transduction and pharmacogenomics in heart failure.  Nature.  2; 475-483. 
 
19. Giessler, C., Dhein, S., Ponicke, K., and Brodde, O.  (1999).  Muscarinic 
receptors in the Failing human heart.  European Journal of Pharmacology.  375; 
197-202. 
 
20. Hall, J.L, Fermin, D.R., Birks, E.J., Barton, P.J.R., Slaugher, M., Eckman, P., 
Baba, H.A., Wohlschlaeger, J., and Miller, L.W.  (2011).  Clinical, molecular, and 
genomic changes in response to a left ventricular assist device.  Journal of the 
American College of Cardiology.  57; 641-652. 
 
21. Heart Failure.  American Heart Association.  Retrieved August 2009 from 
    http://www.americanheart.org/presenter.jhtml?identifier=1486. 
 
22. Hellgren, I., Mustafa, A., Riazi, M., Suliman, I., Sylven, C., and Adem, A.  
(2000).  Muscarinic M3 receptor subtype gene expression in the human heart.  
Cellular and Molecular Life Sciences.  57; 175-180. 
 
 92
23. Houser, S.R., Piacentine, V., and Weisser, J.  (2000).  Abnormalities of calcium 
cycling in the hypertrophied and failing heart.  Journal of Molecular and Cellular 
Cardiology.  32; 1595-1607. 
 
24. Jaski, B.E., Jessup, M.L., Mancini, D.M., Cappola, T.P., Pauly, D.F., Greenberg, 
B., Borow, K., Dittrich, H., Zsebo, K.M., and Hajjar, R.J.  (2009).  Calcium 
upregulation by percutaneous administration of gene therapy in cardiac disease 
(CUPID trial), a first-in-human phase ½ clinical trial.  Journal of Cardiac Failure.  
15; 171-181. 
 
25. Katz, A.M.  (1992).  Physiology of the Heart.  2nd Edition.  Raven Press, Ltd. 
 
26. Keys, J. R. and Koch, W. J.  (2004).  The adrenergic pathway and heart failure.  
Recent Progress in Hormone Research.  59; 13-30. 
 
27. Kroeze, W. K., Sheffler, D. J., and Roth, B. L.  (2003).  G-protein-coupled 
receptors at a glance.  Journal of Cell Science.  116;4867-4869. 
 
28. Kuhn, M., Voss, M., Mitko, D, et al.  (2004).  Left ventricular assist device 
support reverses altered cardiac expression and function of natriuretic peptides 
and receptors in end-stage heart failure.  Cardiovascular Research.  64; 308-314. 
 
29. Lahiri, M. K, Kannankeril, P. J., and Goldberger, J. J.  (2008).  Assessment of 
autonomic function in cardiovascular disease.  Journal of the American college of 
Cardiology. 51; 1725-1733. 
 
30. Landzberg, J.S., Parker, J.D., Gauthier, D.F., and Colucci, W.S.  (1994).  Effects 
of intracoronary acetylcholine and atropine on basal and dobutamine-stimulated 
left ventricular contractility.  Circulation.  89; 164-168. 
 
31. Left Ventricular Assist Device.  American Heart Association.  Retrieved July 
2009 from http://www.americanheart.org/presenter.jhtml?identifier=4599.   
 
32. LeGuludec, D., Cohen-Solal, A., Delforge, J., Delahaye, N., Syrota, A., and 
Merlet, P.  (1997).  Increased myocardial muscarinic receptor density in 
idiopathic dilated cardiomyopathy.  Circulation.  96; 3416-3422. 
 
33. Li, M., Zheng, C., Sato, T., Kawada, T., Sugimachi, M., and Sunagawa, K.  
(2004).  Vagal nerve stimulation markedly improves long-term survival after 
chronic heart failure in rats.  Circulation.  109; 120-124. 
 
34. Lloyd-Jones, D., Adams R.J., Brown, T.M., et al.  (2010).  Heart disease and 
stroke statistics – 2010 update.  A report from the AHA statistics committee and 
stroke statistics subcommittee.  Circulation.  121; e1-e170. 
 
 93
35. Lymperopoulos, A., Rengol, G., Funakoshi, H., Eckhart, A. D., and Koch, W. J.  
(2007).  Adrenal GRK2 upregulation mediates sympathetic overdrive in heart 
failure.  Nature.  13; 315-323. 
 
36. Medline Plus: Heart Failure.  U.S. National Library of Medicine and The National 
Institute of Health.  Retrieved July 2009 from 
www.nlm.nih.gov/medlineplus/heartfailure.html. 
 
37. Mertens, M.J.F., Batink, H.D., Mathy, M-J., Pfaffendorf, M., and van Zwieten, 
P.A.  (1995).  Reduced muscarinic cholinoceptor density and sensitivity in various 
models of experimental cardiac hypertrophy.  Journal of Autonomic 
Pharmacology.  15; 465-474. 
 
38. Mirro, M.J., Manalan, A.S., Bailey, J.C., and Watanabe, A.M.  (1980).  
Anticholinergic effects of disopyramide and quinidine on guinea pig myocardium.  
Circulation Research.  47; 855-865. 
 
39. Mori, K., Hara, Y., Saito, T., Masuda, Y., and Nakaya, H.  (1995).  
Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells.  
Circulation.  91; 2834-2843. 
 
40. Mudd, J. O., and Kass, D. A.  (2008).  Tackling heart failure in the twenty-first 
century.  Nature.  451; 919-928. 
 
41. Nakajima, T., Kurachi, Y., Ito, H., Takikawa, R., and Sugimoto, T.  (1988).  Anti-
cholinergic effects of quinidine, disopyramide, and procainamide in isolated atrial 
myocytes:  Mediation by different molecular mechanisms.  Circulation Research.  
64; 297-303. 
 
42. Ogletree-Hughes, M.L., Stull, L.B., Sweet, W.E., Smedira, N.G., McCarthy, 
P.M., Moravec, C.S.  (2001).  Mechanical unloading restores beta-adrenergic 
responsiveness and reverses receptor downregulation in the failing human heart.  
Circulation.  104; 881-886. 
 
43. Oka, T. and Komuro, I.  (2008).  Molecular mechanisms underlying the transition 
of cardiac hypertrophy to heart failure.  Circulation.  Suppl A: A-13-A-16.  
 
44. Olshansky, B., Sabbah, H. N., Hauptamn, P. J., Colucci, W. S.  (2008).  
Parasympathetic nervous system and heart failure:  Pathophysiology and potential 
implications for therapy.  Circulation.  118:863-871.   
 
45. Peralta, E. G., Ashkenazi, A., Winslow, J. W., and Smith, D. H.  (1987).  Distinct 
primary structures, ligand-binding properties and tissue-specific expression of 
four human muscarinic acetylcholine receptors.  The EMBO Journal.  6;3923-
3929.    
 
 94
46. Perez, C.C.N., Tobar, I.D.B., Jimenez, E., Castaneda, D., Rivero, M.B., 
Concepcion, J.L., Chiurillo, M.A., and Bonfante-Cabarcas, R.  (2006).  Kinetic 
and molecular evidences that human cardiac muscle express non M2 muscarinic 
receptor subtypes that are able to interact themselves.  Pharmacological 
Research.  54; 345-355. 
 
47. Rockman, H. A., Koch, W. J., and Lefkowitz, R. J.  (2002).  Seven-
transmembrane-spanning receptors and heart function.  Nature.  415;206-212.  
 
48. Rose, E.A., Gelijns, A.C., Moskowitz, A.J., Heitjan, D.F., Stevenson, L.W., 
Dembitsky, W., Long, J.W., Ascheim, D.D., Tierney, A.R., Levitan, R.G., 
Watson, J.T., and Meier, P.  (2001).  Long-term use of a left ventricular assist 
device for end-stage heart failure.  The New England Journal of Medicine.  345;  
1435-1443. 
 
49. Saladin, K.  (2007).  Anatomy and Physiology, The Unity of Form and Function.  
Fourth Edition.  564-578. 
 
50. Schmitz, W., Boknik, P., Linck, B., and Muller, F. U.  (1996).  Adrenergic and 
muscarinic receptor regulation and therapeutic implications in heart failure.  
Molecular and Cellular Biochemistry.  157; 251-258. 
 
51. Schwartz, P.J., De Ferrari, G.M., Sanzo, A., Landoline, M., Rordorg, R., Raineri, 
C., Campana, C., Revera, M., Ajmone-Marsan, N., Tavazzi, L, and Odero, A.  
(2008).  Long term vagal stimulation in patients with advanced heart failure First 
experience in man.  European Journal of Heart Failure.  884-891. 
 
52. Shi, H., Wang, H., and Wang, Z.  (1999).  Identification and characterization of 
multiple subtypes of muscarinic acetylcholine receptors and their physiological 
functions in canine hearts.  Molecular Pharmacology.  55; 497-507. 
 
53. Terracciano, C.M., Koban, M.U., Soppa, G.K., et al.  (2007).  The role of the 
cardiac Na+/Ca2+ exchanger in reverse remodeling: relevance for LVAD-
recovery.  Annals of the New York Academy of Sciences.  1099; 349-360. 
 
54. Tracey, K.J.  (2002).  The inflammatory reflex.  Nature.  420; 853-859. 
 
55. Triposkiadis, F., Karayannis, G., Giamouzis, G., Skoularigis, J., Louridas, G., and 
Butler, J.  (2009).  The sympathetic nervous system in heart failure.  Journal of 
the American College of Cardiology.  54:19; 1747-1762. 
 
56. Vatner, D.E., Lee, D.L., Schwarz, K.R., Longabaugh, J.P., Fujii, A.M., Vatner, 
S.F., and Homcy, C.J.  (1988).  Impaired cardiac muscarinic receptor function in 
dogs with heart failure.  Journal of Clinical Investigation.  81; 1836-1842. 
 
 95
 96
57. Vatner, D.E., Sato, N., Galper, J.B., and Vatner, S.F.  (1996).  Physiological and 
biochemical evidence for coordinate increases in muscarinic receptors and Gi 
during pacing-induced heart failure.  Circulation.  94; 102-107. 
 
58. Wang, H., Han, H., Zhang, L., Shi, H., Schram, G., Nattel, S., and Wang, Z.  
(2001).  Expression of multiple subtypes of muscarinic receptors and cellular 
distribution in the human heart.  Molecular Pharmacology.  59; 1029-1036. 
 
59. Wexler, R., Elton, T., and Pleister, A.  (2009).  Cardiomyopathy:  An overview.  
American Family Physician.  79; 778-784. 
 
60. Wilkinson, M., Giles, Al, Armour, A., and Cardinal, R.  (1996).  Ventricular, but 
not atrial, M2-muscarinic receptors increase in the canine pacing-overdrive model 
of heart failure.  Canadian Journal of Cardiology.  11; 71-76. 
 
61. Zhang, Y., Popovic, Z.B., Bibevski, S., Fakhry, I., Sica, D.A., Van Wagoner, 
D.R., and Mazgalev, T.N.  (2009).  Chronic vagus nerve stimulation improves 
autonomic control and attenuates systemic inflammation and heart failure 
progression in a canine high-rate pacing model.  Circulation.  2; 692-699. 
 
62. Zhao, Q., Huang, C., Liang, J., Chen, H, Yang, B., Jiang, H., and Li, G.  (2008).  
Effect of vagal stimulation and differential densities of M2 receptor and Ik,Ach in 
canine atria.  International Journal of Cardiology.  126; 352-358. 
 
